Bitcoin volatility remains a feature of the crypto investing landscape
getty
The recent drop in the price of bitcoin, and by extension the wider cryptoasset ecosystem, contains several important lessons for investors. For contextual purposes the price per bitcoin briefly dropped below $100,000 in November for the first since June before recovering some stability. Bitcoin, and the cryptoasset community more broadly, is no stranger to volatility or longish periods of bearish performance. Seasoned investors who have experienced prior downturns such as 2018-2019 and the post-FTX collapse drawdown will understand that volatility remains an embedded aspect of the cryptoasset class. Even following the change in administration in Washington D.C. and the flurry of policy changes that have benefited the crypto sector, adoption among both individuals and institutions remain a work in progress.
Given the ongoing geo-political tensions, trade disputes, and government shutdown that continues to paralyze decision-making at the policy level it is interesting to note how well both crypto and equity markets have dealt with these challenges. As with any bearish downturn or even a short-turn drop in price, however, there are lessons that can – and should be – learned from recent market volatility.
Let’s take a look at several lessons and takeaways that crypto investors should keep in mind as crypto volatility returns, policy makers remain sidelined, and the market continues to mature.
AI & Crypto Continue To Be LinkedWhile AI and automated trading bots have long been dominant in the traditional financial markets and ecosystems, the integration of AI within the crypto sector is accelerating. In the period of just a few weeks in 2025 the market capitalization of AI crypto agents jumped 29% to over $31 billion, and outperformed manual traders by between 15-25% during that same period. For the cryptoasset sector, which has experienced volatility through its history, having bots that are available 24/7 to continuously analyze market patterns, refine trading strategies, and leverage these insights to mitigate risk as well as improving forecasting ability, the benefits are quantifiable and only increasing.
Even more pointedly the intersection between the crypto mining sector and the AI industry has accelerated via recent deals due to the fact that both industries require energy, processing power, and the facilities to host these server farms. As both sectors continue to experience wider adoption among institutional users the power demand, and become lumped together within the broader technology asset class, trading patterns and fund flows continue to merge.
MORE FOR YOU
Investors need to simply look at the recent sell-off of (potentially) over-inflated AI valuations and the associated crypto drawdown to see evidence of this convergence.
Crypto Is A Risk-On AssetFollowing the approval of the spot bitcoin ETF by the SEC in January 2024 a primary driving force behind the following rally and increase in price of bitcoin and other cryptoassets has been the inflow of institutional funds into the space. Many of the forecasts put forward by TradFi institutions for bitcoin were built on the assumption that ETF fund flows would continue to increase as larger buyers continued to enter the space. As geo-political tensions and trade disputes have continued to escalate, however, the impact on crypto trading patterns and volumes have reflected this. With newer investors, including both institutional and retail investors, having entered the space more recently during the bull market, losses and drawdowns are highlighting the risk-on nature of bitcoin and crypto at large.
As the fund flows into ETFs have slowed recently, larger wallets (holders) of bitcoin have been incrementally selling, and the number of retail wallets have increased this has created a sentiment that is incrementally less bullish than previously forecasted. With the direction of rate decisions at the Federal Reserve uncertain, economic data declining in quality, and trade tensions increasing while the government shutdown continues the risk-on nature of crypto – built on the previous 12 months of positive sentiment and gains – is exposing investors to downside risk as economic conditions remain volatile.
Volatility Remains A FeatureVolatility remains an embedded feature of the cryptoasset ecosystem, rather than a bug that needs to be hedged and/or mitigated out of the marketplace. Despite the recent policy progress, institutional investment and fund flows, and the general pivot in the United States to a pro-technology (including both AI and crypto) the crypto sector remains an emerging asset class. To put the size of the market in context, the crypto sector is worth in excess of $3 trillion, which represents significant growth, but pales in comparison to the trading volume and market capitalization of more established asset classes.
Highlighting this reality is the fact that the price of bitcoin, the gold-standard of crypto from an institutional investing perspective, routinely moves up and down by double-digit percentages. Such volatility would be the cause of incessant market analysis and media commentary if experienced by a leading equity, but for crypto investors this volatility remains a familiar and embedded aspect of the investing thesis. Crypto has come a long way in terms of investor education, policy wins, and investing fund flows but volatility, driven by either market forces or external forces, remains a feature as the market continues to mature.
2025-11-09 22:305mo ago
2025-11-09 14:505mo ago
Coinidol.com: Litecoin Drops To Its Range Above $80
Litecoin (LTC) has not risen since moving above the moving average lines. The cryptocurrency climbed above these lines but encountered resistance
The cryptocurrency climbed above these lines but encountered resistance around $110. After reaching this recent high, it fell below the 50-day SMA.
Litecoin price long-term prediction: bullish
On the downside, selling pressure is expected to persist above the 21-day SMA support, or the $95 low. If bears push the price below the moving average lines, negative momentum could drive it down to $80.
Currently, Litecoin is trading below the 50-day SMA support and above the 21-day SMA support. When the moving average lines are breached, the altcoin tends to establish a new trend. Litecoin is now valued at $100.27.
Technical Indicators
Resistance Levels: $100, $120, $140
Support Levels: $60, $40, $20
Litecoin indicator analysis
The price bars are positioned above the horizontal moving average lines. However, bears are attempting to push the price below the 50-day SMA. If they succeed, Litecoin's price could decline significantly. On the 4-hour chart, the price bars remain above the horizontal moving average.
What is the next move for Litecoin?
Litecoin's price is rising while maintaining a sideways trend. There are long candlestick wicks at several price levels, indicating significant selling pressure at recent highs. Currently, the cryptocurrency is declining as it returns to its previous price range above $80.
Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds.
2025-11-09 22:305mo ago
2025-11-09 15:005mo ago
XRP New Investors and Profits Decline – Will Price Face Another Correction?
New XRP address growth has declined sharply, signaling weakening investor participation and limited demand for the token.Long-term holders’ profits have fallen as the MVRV ratio dips, increasing the risk of mild selling pressure.XRP could consolidate between $2.28 and $2.13 unless renewed inflows push the price above $2.36 resistance.XRP has traded sideways for several days, struggling to find momentum amid weak market conditions. The lack of bullish signals across the broader crypto sector has left the token consolidating near key support levels.
Adding pressure, investor participation, and profitability are all declining, hinting at potential downside risks.
XRP Investors Pull BackNew XRP addresses have seen a noticeable drop, reflecting waning interest from fresh investors. Earlier this month, new wallet creation surged to a four-month high but has since fallen sharply to around 6,336. This cooling growth signals that new buyers see little incentive to invest in XRP at current levels.
Sponsored
Sponsored
Such a decline in participation can weaken liquidity and stall price recovery. Without an influx of new capital, the demand needed to push XRP higher may be missing. If this trend continues, the altcoin could remain rangebound.
Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.
XRP New Addresses. Source: GlassnodeThe MVRV Long/Short Difference currently sits near 3%, reflecting shrinking profits for long-term holders (LTH). Historically, positive readings indicate healthy profitability, while declining values point to eroding gains. The recent dip suggests that even experienced investors are seeing lower returns from their holdings.
If long-term holders start realizing profits or exiting positions, this could add selling pressure to XRP’s price. Sustained declines in the MVRV ratio often coincide with reduced confidence, increasing the likelihood of minor corrections.
XRP MVRV Long/Short Difference. Source: SantimentXRP Price May Need A PushXRP is trading at $2.32, holding above the crucial $2.28 support level. The altcoin has made multiple attempts to breach $2.36 but has struggled to sustain momentum amid weak investor participation.
Given the current on-chain and technical setup, XRP could continue consolidating between $2.28 and $2.13 if selling pressure grows. A break below $2.13 would reinforce the bearish outlook and delay recovery.
XRP Price Analysis. Source: TradingViewHowever, if investor confidence improves and inflows strengthen, XRP could successfully flip $2.36 into support. This move would open the path toward $2.45 or even $2.52, signaling renewed bullish sentiment and invalidating the current bearish thesis.
Disclaimer
In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.
2025-11-09 22:305mo ago
2025-11-09 15:005mo ago
XRP Ready For The 5th Wave: Analyst Says Don't Fight It
XRP has spent the past week on the continuation of a downtrend from the previous week, slipping from above $2.50 before rebounding around $2.12 and now hovering around $2.30. The price action reflects a market struggling to find direction, caught between bullish optimism and lingering selling pressure.
Despite the broader slowdown in its price action, technical analysis shows that XRP is still displaying a resilient structure on the charts that maintains its critical support levels. According to Egrag Crypto, a popular analyst known for his long-term technical outlooks on XRP, the token may soon enter what will become the most explosive fifth wave yet.
XRP Elliott Wave Analysis: ‘The Power Of 5’
Egrag Crypto’s latest technical analysis on the social media platform X points to the fact that XRP is in the final stages of its fourth impulse wave, which is a corrective wave based on the popular Elliott Wave Theory. Notably, this movement is now setting up for the beginning of the fifth wave, which is a bullish impulse under the same theory.
Looking at previous cycles on the 5-day candlestick timeframe chart, particularly during 2017 and 2021, showed that similar setups came before massive upward surges in XRP’s price. The analyst’s chart displays a repeating structure of five-wave patterns, each representing major bullish impulses in the token’s history.
The chart also reflects the distinct cyclical rhythm of XRP’s price behavior over the years. Each major impulsive phase (waves 1, 3, and 5) has always been followed by smaller corrective waves (2 and 4), a structure that continues to repeat with precision.
XRP is currently trading at $2.27. Chart: TradingView
The overlapping bands in cyan and pink, representing exponential moving averages, now point to XRP consolidating within a strong support region around $2.20, which indicates that the fourth impulse wave is coming to an end.
XRP Technical Analysis: Source @egragcrypto on X
Analyst Says Don’t Fight It
By Egrag Crypto’s measure, the ongoing consolidation might be setting the stage for a similar move to double-digit prices if the fifth wave unfolds as projected.
The visual projection marks potential Fibonacci extensions of 1.272, 1.414, 1.618, and 2.618 at $4.789, $5.515, $6.755, and $18.259 as possible long-term targets once the fifth wave takes hold. These levels may act as resistance points in the impending bull phase because they resemble the wave geometry that drove XRP’s earlier rallies in 2017 and 2021.
Interestingly, the analyst also referenced how skepticism often peaks before major rallies. He reminded followers of a trader who lost $30 million shorting XRP during its last major uptrend in 2024. As such, the analyst concluded by urging traders not to “fight the fifth wave” but to “ride it.”
At the time of writing, XRP is trading at $2.27, down by 1.6% and 9.2% in the past 24 hours and seven days, respectively.
Featured image from Unsplash, chart from TradingView
2025-11-09 22:305mo ago
2025-11-09 15:005mo ago
BNB tumbles 10% as CZ reacts in surprise to pardon – Here's what it means for Binance
Key Takeaways
Why is BNB dropping this week?
BNB is down nearly 10% after failing to recover above $1,000.
What’s happening in the derivatives market?
Open interest remains flat near $866M, showing that traders are cautious and not taking big leveraged positions in either direction.
Binance Coin [BNB] is sliding again. The coin is down almost 10% this week, and the Derivatives market is confirming the hesitation.
Source: CoinMarketCap
The timing is awkward too: Binance Co-Founder CZ publicly reacted to news of a presidential pardon with visible surprise, insisting he has no connection to the Trumps.
BNB momentum fades
BNB has dropped nearly 10% this week, and the technicals align with that slowdown.
On the daily chart, price failed to recover above the $1,000 zone, while volume remained muted. Traders appeared unwilling to chase dips.
Source: TradingView
RSI was near 41, which is bearish but not washed-out enough to indicate capitulation. Meanwhile, MACD remained deep in negative territory, so the downtrend was still dominant at press time.
Put simply, this is controlled weakness. But without a surge in demand, BNB risks drifting lower before seeing meaningful support.
Derivatives stay quiet
Open Interest has barely moved this week, holding near $866 million. The chart showed a flatline that is indicative of traders’ hesitation.
Source: Coinalyze
The Aggregated Funding Rates also moved close to 0.0005%, showing a lack of leverage pressure from either longs or shorts. There’s no big money betting aggressively in either direction.
Despite BNB’s price drop, Derivatives traders seem content to wait things out, keeping activity subdued and momentum weak at press time.
CZ speaks out during controversy
2025-11-09 22:305mo ago
2025-11-09 15:005mo ago
Crypto-treasury stocks sink as Bitcoin and Ether sell off
Crypto‑treasury stocks, which rallied when companies stuffed their balance sheets with Bitcoin and ether, are sinking after recent price drops. For much of the year, investors were selling shares or borrowing funds to buy crypto, betting that corporate treasuries loaded with tokens would outperform holding the coins directly.
2025-11-09 22:305mo ago
2025-11-09 15:105mo ago
Will History Repeat? Bitcoin Traders Eye Rally as US Shutdown Deal Nears
After 40 days of political gridlock, the US federal government appears close to reopening, and crypto traders are once again betting that history may repeat itself.
2025-11-09 22:305mo ago
2025-11-09 15:125mo ago
Beep prepares on Sui, Bringing AI-Powered Agentic Finance to DeFi
In a groundbreaking move for decentralized finance, Beep has officially launched on the Sui blockchain, unveiling what it calls the world's first agentic wallet and finance protocol. The initiative blends artificial intelligence (AI) with DeFi infrastructure, introducing a new era of AI-driven financial automation, zero-fee payments, and real-time transactions across global markets.
2025-11-09 22:305mo ago
2025-11-09 15:195mo ago
Institutional Investors Turn Their Backs on Bitcoin and Ethereum
In one week, spot ETFs backed by ether (ETH) saw about $508M in withdrawals, while Bitcoin ETFs also recorded notable outflows. The movement is not trivial. It reflects market sentiment, risk management arbitrage, and how institutional investors are now recalibrating their exposure to crypto assets.
In Brief
Ethereum spot ETFs register $508M outflows, while Bitcoin also sees withdrawals
The movement reflects institutional rotation: beta reduction, ETH/BTC arbitrage and more tactical risk management
In the short term, these flows weigh on spot but create entry windows, to be monitored via basis/funding.
$508M Exits from Ethereum and Bitcoin ETFs, Sign of Arbitrage and Tactical Caution
A spot ETF is not just a market note: it captures real flows, backed by reserves of underlying assets. As JPMorgan points out, client interest in spot Bitcoin ETFs is intensifying, signaling a redeployment of demand towards spot exposure. When investors lighten up, the issuer mechanically reduces its positions in ether or bitcoin. Result: capital contracts on one side, reinjects on the other, and liquidity reorganizes at the pace of institutional arbitrage.
The fact that Ethereum and Bitcoin record simultaneous outflows suggests a collective move. No panic. Rather a quick normalization of risk. Traders reduce, take profits, lighten the delta. In short, they become tactical again.
ETF withdrawals can temporarily weigh on the spot price. Not systematically: it all depends on order book depth and hedges already in place via futures and options. But, marginally, these flows matter and accelerate internal rotations between assets, including between ether and bitcoin.
Institutional Caution: Defensive Tactic or Assumed Rotation?
Analysts see it as short-term caution. That is consistent. When macro visibility becomes murky, the reflex is to reduce beta exposure, keep higher conviction positions. The ETF becomes the ideal control. One click, one allocation moves.
But one should not confuse withdrawals with disenchantment. An ETF outflow may be only the visible leg of a broader strategy: taking profit on spot, reopening via derivatives, buying options in the distribution tail. In other words, closing with one hand, re-encoding risk with the other. It’s clean, efficient, measurable.
Moreover, the ETH/BTC relationship remains central. When the market anticipates a phase of bitcoin dominance (narrative “digital reserve”, deeper institutional demand), it is logical to see arbitrage disadvantaging ETH in the short term. Then, often, the balance rebalances when approaching catalysts specific to the Ethereum ecosystem. Patience and granularity.
Market Consequences
Massive withdrawals concentrated over a few sessions can thin out order books. This creates “price gaps.” For a patient operator, these gaps are entry windows. Not in all-in mode. In ladder mode. Step by step. With smart stops and adjusted sizes.
The basis/funding spread between spot and derivatives: outflows from ETFs, combined with easing funding, signal selling pressure being absorbed. If the basis remains positive but more measured, the market catches its breath.
Maximize your Cointribune experience with our "Read to Earn" program! For every article you read, earn points and access exclusive rewards. Sign up now and start earning benefits.
Join the program
A
A
Lien copié
Evans S.
Fascinated by Bitcoin since 2017, Evariste has continuously researched the subject. While his initial interest was in trading, he now actively seeks to understand all advances centered on cryptocurrencies. As an editor, he strives to consistently deliver high-quality work that reflects the state of the sector as a whole.
DISCLAIMER
The views, thoughts, and opinions expressed in this article belong solely to the author, and should not be taken as investment advice. Do your own research before taking any investment decisions.
2025-11-09 22:305mo ago
2025-11-09 15:295mo ago
BTC and crypto sell-off reminiscent of post-2000 dot-com crash: Analyst
Large, long-term crypto and Bitcoin investors continue to sell into the market, keeping asset prices from hitting a blow-off top.
1395
Crypto whales and long-term holders are cashing out, exerting constant selling pressure on markets, and keeping crypto prices suppressed, similar to market dynamics following the 2000s dot-com stock market crash, according to analyst Jordi Visser.
Visser said the current price action in the crypto market is reminiscent of the period following the 2000 dot-com stock market bubble, which crashed stocks by up to 80%, followed by 16 years of consolidation before they regained their previous highs.
This meant that venture capitalists, who invested in tech during the crash, were forced to hold their investments due to mandated lock-up periods as they treaded water and then desperately sold into the markets as soon as they were able to, Visser said. He added:
“Many stocks were trading below their IPO prices. We have a similar situation going on right now. VC and insider investors, desperate for liquidity or redemption, sold into every rally. That's what's happened to me for Solana, Ethereum, for every altcoin, and for Bitcoin.”The US stock market took about 16 years to recover to its previous all-time high and was suppressed by large investors selling into the market. Source: Jordi VisserVisser clarified that it would not take 16 years for crypto prices to rebound, but was using the 2000s dot-com aftermath to illustrate the sell-side pressure dynamics at play, and said crypto is nearing the end of this consolidation phase, with a maximum of 1 year left.
Has Bitcoin bottomed out around the $100,000 level?The price of BTC shows signs of bottoming out around $100,000, according to some analysts, but others fear a potential drop to $92,000 if selling pressure continues to mount.
Whales and long-term holders typically cash in at all-time highs, and whale selling is not a problem in and of itself, CryptoQuant analyst Julio Moreno said.
Long-term BTC holders are now dumping their coins onto the market faster than the market can absorb the supply. Source: Julio MorenoThe sell-side pressure from whales and long-term holders only suppresses asset prices if new demand is not there to soak up the BTC supply being dumped on the markets.
“Since October, long-term holder selling has increased; nothing new here, but demand is contracting, unable to absorb long-term holder supply at a higher price,” Moreno said.
Magazine: Altcoin season 2025 is almost here… but the rules have changed
2025-11-09 22:305mo ago
2025-11-09 15:405mo ago
Mysticeti v2 Boosts Sui Blockchain Speed with Smarter Transaction Consensus
Mysten Labs has rolled out Mysticeti v2, a major upgrade to its consensus protocol that significantly enhances the performance of the Sui blockchain. The update introduces faster transaction processing, lower resource consumption, and improved network resilience — further positioning Sui as one of the most efficient and scalable Layer-1 blockchains in the industry.
2025-11-09 22:305mo ago
2025-11-09 15:535mo ago
Privacy Coins Ignite: Zcash, Monero and Others Rocket as Investors Chase Anonymity-Driven Tech
On Sunday, privacy coins put on a show as zcash (ZEC) leapt 12.8% to crack the $640 mark, while monero ( XMR) sprinted 21% to sail past $440 per coin. Privacy tokens are clearly basking in the spotlight right now—and the crowd's loving it.
2025-11-09 22:305mo ago
2025-11-09 16:005mo ago
Mapping Dogecoin's path – Price could chase THIS before sliding to $0.13
Key Takeaways
Is there evidence that sentiment has turned bullish for Dogecoin?
No, the Elon Musk post a few days ago and the recent price bounce saw a brief spike in social media engagement, but nothing sustained to reverse the downtrend.
What should DOGE traders expect now?
The $0.18-$0.19 was a key resistance zone and a rejection from here was underway, with the next price targets being $0.15 and $0.13.
Dogecoin [DOGE] and the memecoin market have shed 31% in value over the past month, according to CoinMarketCap data. Elon Musk’s post on X saw a social media buzz that price did not follow.
The decline in Open Interest in recent hours was accompanied by a retest of a resistance zone at $0.18. In the past 24 hours, DOGE was down by 2.67%, and its OI is down 3.66%. It signaled short-term bearishness.
Is this a signal for traders to go short? AMBCrypto examined the price charts to forecast the next move and also plot where its invalidation lies.
The rejection at KEY support shows a bearish Dogecoin
Source: DOGE/USDT on TradingView
Last week’s bearish forecast proved right, and a Dogecoin price move to $0.15 has materialized. At the time of writing, the rejection from the $0.18 level was a sign that the bears were still in power on the 1-day timeframe.
Lower-timeframe metrics supported this bias: both Open Interest and short-term price performance showed persistent selling pressure.
The daily timeframe has a bearish structure and a steady downtrend in the OBV. The MFI also signaled that sellers were in control.
Together, they showed why the $0.18 former support would likely be the beginning of a downward move that reaches $0.15 again, and possibly as low as the $0.13 support.
The bearish structure would be broken if Dogecoin can climb back above $0.209.
Liquidity data hints at ONE last squeeze
The 2-week Liquidation Heatmap highlighted the presence of liquidity overheat at $0.19 and $0.204. These short liquidations might be targeted before a price drop toward $0.13.
Watch out for a trend shift on the 1-day timeframe’s OBV, combined with a move past $0.209, for the beginning of an uptrend.
Until then, a potential bounce, even as high as $0.204, would be for selling.
Disclaimer: The information presented does not constitute financial, investment, trading, or other types of advice and is solely the writer’s opinion
Akashnath S is a Senior Journalist and Technical Analysis expert at AMBCrypto. He specializes in dissecting price action, identifying key market trends through advanced chart patterns, and forecasting both short-term and long-term asset trajectories.
His distinct analytical method is grounded in his academic training as a Chemical Engineer. This background provides him with a systematic, process-oriented approach to market data, enabling him to analyze the complex dynamics of financial markets with precision and objectivity.
Having actively covered the cryptocurrency space since the landmark 2017 market cycle, Akashnath possesses years of experience navigating both bull and bear markets. This seasoned perspective is critical to his insightful reporting on market volatility and evolution.
As an active market participant, Akashnath enhances his analysis with crucial, hands-on experience. This practical application of his technical skills ensures his insights are not merely theoretical, but are also relevant and actionable for an audience looking to understand and navigate trading opportunities. He is dedicated to educating readers on the nuances of technical analysis, empowering them with the knowledge to make more informed financial decisions.
By just about every possible metric, Cardano continues to disappoint investors.
For years, crypto industry insiders have been expecting a big breakout for Cardano (ADA +2.68%). Unfortunately, that moment has never arrived. Cardano is down 30% for the year, and more than 80% from its all-time high of $3.10.
So, does Cardano have a future?
Investor demand for Cardano
One way to answer that question is by examining how much demand there is for Cardano from both retail and institutional investors. The higher the demand, the brighter the future should be for Cardano. And, conversely, the lower the demand, the dimmer its future prospects might be.
Given all the buzz about new exchange-traded funds (ETFs) for top altcoins, this should be one area where Cardano really shines. But that's simply not the case. When it comes to upcoming spot Cardano ETF filings, there's not much on the docket.
BlackRock (BLK +1.19%) -- the company behind the most popular spot crypto ETF -- has not filed an application for a spot Cardano ETF. Investment firm Grayscale plans to offer a spot Cardano ETF, but that's about it.
Image source: Getty Images.
Right now, all the buzz from investors is for potential XRP (XRP +2.21%) and Solana (SOL +4.45%) ETFs. Even Litecoin (LTC +9.95%) -- a cryptocurrency that is at risk of falling out of the list of the top 20 most popular cryptocurrencies in the world -- is getting more attention than Cardano right now.
That tells you all you need to know. Investors simply aren't that excited about Cardano. If they were, investment management firms would be rushing to create new investment products.
The numbers bear this out. Every week, CoinShares publishes updated institutional fund flows into major cryptocurrencies, and the amount of money that has flowed into Cardano year to date is minimal at best. A grand total of $50 million has flowed into Cardano in 2025. By way of comparison, $29 billion has flowed into Bitcoin (BTC +2.40%) and $14 billion has flowed into Ethereum (ETH +5.31%).
Blockchain metrics for Cardano
So why aren't investors excited about Cardano? Part of the answer has to do with the fact that Cardano has long been known as the blockchain where nothing happens. Some have even referred to Cardano as a "ghost chain," implying that it's a blockchain with limited real-world utility.
Today's Change
(
2.68
%) $
0.02
Current Price
$
0.58
In terms of users, projects, and transactions, the Cardano blockchain is not nearly as active as competitor blockchains such as Ethereum. That's really a shame, because the co-founder of Cardano, Charles Hoskinson, is also one of the co-founders of Ethereum. Thus, in many ways, the same blockchain DNA used to create Ethereum was also used to create Cardano.
Yet, the difference between the two couldn't be more stark. Take Total Value Locked (TVL), for example. This is a key metric for measuring overall blockchain activity, and a good barometer for measuring activity related to decentralized finance (DeFi).
Ethereum is the clear leader in this regard, accounting for 63% of all TVL in the blockchain world. Cardano, by way of comparison, barely registers as a blip on the radar screen. Even upstarts such as Aptos (APT +5.14%) and Sui (SUI +2.01%) have now passed Cardano, which ranks 24th overall among all blockchains.
Should you buy Cardano?
Admittedly, Cardano has an impeccable blockchain pedigree. It still ranks among one of the top 10 cryptocurrencies in the world, with a $20 billion market cap. And it does have a vast developer network committed to its future growth. It's certainly not a fly-by-night crypto that's going to disappear overnight.
However, since launching in 2017, Cardano has never traded higher than $3.10 -- and that was more than 4 years ago. Since then, Cardano has had plenty of opportunities to get involved with hot new innovations in the blockchain world -- from AI to stablecoins to tokenized assets -- and has shown little ability to do so.
For that reason, it's time to look elsewhere for upside. Cardano may be able to double in value to hit a price of $1 within the next 24 months, but asking for much more than that is likely asking too much.
Dominic Basulto has positions in Bitcoin, Cardano, Ethereum, Solana, Sui, and XRP. The Motley Fool has positions in and recommends Aptos, Bitcoin, Ethereum, Solana, Sui, and XRP. The Motley Fool recommends BlackRock. The Motley Fool has a disclosure policy.
2025-11-09 22:305mo ago
2025-11-09 16:525mo ago
Rift Secures $8 Million for Native Bitcoin on Ethereum
Rift raises $8 million from Paradigm for native Bitcoin on Ethereum.Aims to enhance cross-chain BTC trades.Potentially disrupts DeFi models relying on wrapped BTC.
Rift, a peer-to-peer Bitcoin trading protocol, announced securing $8 million from Paradigm to enhance native Bitcoin trading on Ethereum and other platforms, aiming for a seamless cross-chain experience.
This funding could redefine Bitcoin’s role in DeFi by enabling direct trading without wraps, potentially impacting liquidity pools and existing wrapped Bitcoin models.
Rift Raises $8M to Integrate Bitcoin with Ethereum
Rift’s recent announcement highlights a significant milestone in its mission to integrate native Bitcoin trading with Ethereum, backed by an $8 million investment from Paradigm. The project aims to enable direct Bitcoin interoperability without the need for wrapped tokens. This development represents a potential shift in the crypto landscape, as it eliminates additional custodial risks associated with wrapped assets.
The investment is a strategic move to boost Bitcoin’s integration into Ethereum’s ecosystem and could pioneer new pathways for digital asset transactions.
Market reactions have been noticeably positive, with increased engagement from developers and community members across Ethereum and the broader DeFi ecosystem. Although no official responses have been issued by major crypto figures such as Arthur Hayes or CZ, the community’s excitement suggests that this project is viewed as a major technical advancement.
Expected Impact on DeFi and Market Dynamics
Did you know? Rift’s initiative to integrate native Bitcoin trading on Ethereum mirrors previous technological strides like RenVM. However, Rift’s method signifies advancement due to the non-custodial nature, mitigating previous risks linked with wrapped tokens, potentially altering long-standing approaches in DeFi.
Bitcoin is trading at $104,740.50 with a market cap of $2.09 trillion, reflecting a 2.39% over the past 24 hours, as per CoinMarketCap. Its dominance remains at 59.24%, despite a decline in value over the past 90 days by 11.70%. Trading volume reached $56.61 billion over the last day, marking a 5.90% increase.
Bitcoin(BTC), daily chart, screenshot on CoinMarketCap at 21:47 UTC on November 9, 2025. Source: CoinMarketCap
Experts from the Coincu research team suggest that Rift’s innovation could lead to significant disruptions in traditional DeFi mechanics, particularly those relying on synthetic BTC assets. Such a shift might result in increased regulatory scrutiny as native cross-chain protocols gain traction in large transaction volumes.
DISCLAIMER: The information on this website is provided as general market commentary and does not constitute investment advice. We encourage you to do your own research before investing.
Rate this post
2025-11-09 22:305mo ago
2025-11-09 16:595mo ago
Man Who Once Let Ohio Pay Taxes in Crypto Just Lost $1.2 Million on Bitcoin Options
Josh Mandel, ex-Ohio State Treasurer, revealed losing over $1.2 million on BlackRock's IBIT Bitcoin ETF call options.As Ohio Treasurer, Mandel led the creation of OhioCrypto.com, enabling business tax payments in Bitcoin—a first in U.S. state policy—before the program was suspended by his successor in 2019.Mandel's high-profile loss follows the November 2024 launch of ETF options trading in the U.S., with his transparency serving as a caution.Former Ohio State Treasurer Josh Mandel, once hailed as an early political champion of Bitcoin, has revealed a personal loss of more than $1.2 million on call options tied to BlackRock’s iShares Bitcoin Trust (IBIT).
The former state official’s gamble followed his bold prediction that Bitcoin would reach $444,000 by November 8, a forecast that has clearly not materialized.
Sponsored
Sponsored
Ohio’s Crypto Tax Pioneer Loses $1.2 Million Betting on Bitcoin OptionsMandel shared details of his failed trade in a post on X (Twitter), saying he had gone “all in” on IBIT call options, only to watch them expire worthless.
“Earlier in the cycle, I published a MSTR and MSTR-option-only portfolio. Initially, it was entirely long, then shifted to short with in-the-money covered call sales as I predicted Bitcoin would hit $84,000…These moves worked out well enough, but I grew impatient with my final call for $444,000, and as they say, you’re only as good as your last call,” he wrote.
Mandel added that his post was intended “to be transparent,” rejecting accusations that he misled investors or sought to profit through coin issuance.
Josh Mandel Loses $1.2 Million in Bitcoin Options Trade. Source: Mandel on XLong before retail Bitcoin speculation reached mainstream America, Josh Mandel helped Ohio “plant a flag” for crypto adoption.
In November 2018, as State Treasurer, he launched OhioCrypto.com, the first US government platform allowing businesses to pay state taxes in Bitcoin. The payments, processed through BitPay, were automatically converted into US dollars for the state treasury.
Sponsored
Sponsored
At the time, Mandel described Bitcoin as “a legitimate form of currency” and positioned Ohio as a leader in blockchain innovation.
“We’re looking to plant a flag for Ohio,” he told reporters, arguing that the move would modernize state finances and attract tech-forward businesses.
The program, however, faced regulatory hurdles under his successor, Treasurer Robert Sprague, who suspended it in 2019 after determining that BitPay’s payment structure may have violated state procurement laws. Fewer than ten companies had used the service before it was shut down.
Risks and Lessons From the Bitcoin ETF Options MarketMandel’s high-stakes loss comes as interest in Bitcoin ETF options has surged since their launch in late 2024. As Kaiko research noted, trading volumes in Bitcoin ETF options soared, with many traders favoring bullish positions.
Recently, however, Bitcoin ETFs have not been performing as well, with outflows reaching levels last seen in May. In fact, they only recently recorded the first inflow after a $2.9 billion outflow streak.
Nonetheless, speculative long-term bets like Mandel’s remain outliers, highlighting the significant risks associated with options and the volatility of Bitcoin prices.
By making his investment loss public, Mandel offers a reminder that experienced public figures and crypto pioneers can also misjudge timing or risk in digital assets.
As regulated crypto derivatives expand and attract more investors, Mandel’s experience demonstrates that market predictions, even when widely shared, come with no guarantee of success.
Disclaimer
In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.
2025-11-09 22:305mo ago
2025-11-09 17:005mo ago
Don't Panic — Bitcoin Market Is Only In A Restructuring Phase: Blockchain Firm
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure
The Bitcoin market has been in a state of uncertainty over the past few weeks, following its uncharacteristically negative performance in October. While the general market sentiment suggests that the end of the bull cycle might be near, the latest on-chain data indicates that the premier cryptocurrency might merely be undergoing a reset. According to a blockchain firm’s report, the recent sluggishness seems to be setting the stage for the coin’s next major move.
BTC Not In A Cycle Exhaustion Phase: XWIN
In the latest Quicktake post on the CryptoQuant platform, XWIN Research Japan revealed that the current situation of Bitcoin looks less like the end of a cycle and more like a restructuring phase. The DeFi firm believes that the market foundations are being reset after the clearing out of excess leverage in recent weeks.
Supporting the claim of reduced leverage, XWIN Research highlighted that open interest in the Bitcoin future market has reduced significantly since late October. This decline in open interest signals the exit of short-term traders from their leveraged positions.
The blockchain firm noted that, in past cycle peaks, leveraged trades often increased even at high price levels. However, this euphoric buildup of market positions is not currently the case for Bitcoin, meaning that a cycle top is likely not what is being witnessed.
Source: CryptoQuant
Furthermore, XWIN Research Japan said that the Bitcoin price is currently lacking momentum and not missing structural support. The blockchain firm pinpointed declining demand from United States institutional investors—as spotlighted by the negative Coinbase Premium Index—as one of the factors behind the lack of momentum.
As of this writing, Bitcoin is valued at around $101,930, reflecting no significant movement in the past 24 hours. The flagship cryptocurrency is deep in the red on the weekly timeframe, though, having suffered an 8% price decline in the last seven days.
Bitcoin Market Shows Both Strengths And Weaknesses
Despite the weakened institutional demand for BTC, XWIN Research highlighted some positive signs that could contribute to the cryptocurrency’s eventual recovery. For instance, the DeFi firm revealed that Bitcoin exchange reserves remain at multi-year lows, meaning that a limited supply is still available.
Additionally, stablecoin liquidity is gradually flowing back into the market; this means that purchasing power is also returning, and investors might just be waiting for the right time. However, XWIN Research noted that, despite the obvious market resilience, the current sentiment suggests a range-bound movement in the short term.
The price of BTC on the daily timeframe | Source: BTCUSDT chart on TradingView
Featured image from iStock, chart from TradingView
Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.
Sign Up for Our Newsletter!
For updates and exclusive offers enter your email.
Opeyemi Sule is a passionate crypto enthusiast, a proficient content writer, and a journalist at Bitcoinist. Opeyemi creates unique pieces unraveling the complexities of blockchain technology and sharing insights on the latest trends in the world of cryptocurrencies. Opeyemi enjoys reading poetry, chatting about politics, and listening to music, in addition to his strong interest in cryptocurrency.
2025-11-09 22:305mo ago
2025-11-09 17:005mo ago
Is the Bitcoin treasury ‘bear market' crisis over? Analyst says
Key Takeaways
Why are funds closing MSTR’s short positions?
They believe the thesis has played out as mNAV compresses close to 1.0X.
How can the update impact BTC’s value?
Sellers’ exhaustion could allow bulls to step in for MSTR, and by extension boost inflows into BTC.
The legendary Wall Street short seller, James Chanos, has closed his short position on MSTR stock (Strategy), a trend that’s raising hopes for a potential recovery in treasury inflows.
Chanos explained his firm went short on MSTR and long Bitcoin [BTC], after the company’s mNAV (market-to-net-asset-value) began contracting last year. He added,
“It is prudent to cover this trade with mNAV below 1.25x, having dropped from ~2.0x as recently as July 2025. While we still believe there is more room for mNAV compression, the thesis has largely played out.”
Source: Chano & Co
For context, mNAV measures how a firm’s market value compares to its crypto holdings.
Higher readings indicate rising demand for leveraged BTC exposure via MSTR and, by extension, overvaluation compared to the stock.
However, that ratio has since fallen sharply from 3.4x to nearly 1x, explaining Chanos’ decision to cover his short — a move typically seen as bullish.
Will it improve BTC treasury inflows?
Kerrisdale Capital, another prominent short-seller, made a similar bet against MSTR last year — as well as BitMine, the leading Ethereum [ETH] treasury firm. Both cited inflated mNAVs and competition from Bitcoin ETFs as the core of their bearish theses.
Since July’s high $457, MSTR has dropped over 51% to $219.68, marking a windfall for bears like Chanos and Kerrisdale.
Source: MSTR vs BTC, TradingView
Still, with shorts now being covered, analysts expect near-term relief for MSTR and possibly for BTC treasury inflows.
Pierre Rochard, CEO of treasury firm Bitcoin Bond Company, noted,
“The Bitcoin treasury company bear market is gradually coming to an end. Expect continued volatility, but this is the kind of signal you want to see for a reversal.”
Treasury inflows at a crossroads
During Bitcoin rallies in late 2024 and mid-2025, inflows to Digital Asset Treasuries surged. For instance, weekly inflows tripled from $2 billion to $6 billion in November 2024, according to DeFiLlama.
Source: DeFiLlama
After July 2025, however, the inflows weakened from about $4B to $45 million. A 98% decline in demand from treasury firms as they struggled with compressed mNAVs or the so-called “bear market.”
That said, MicroStrategy recently increased its Euro-based STRE note offering from €350 million to €620 million for fresh BTC purchases.
Still, it remains unclear whether bulls will step in at current MSTR levels to lift mNAV and revive treasury inflows into BTC.
2025-11-09 22:305mo ago
2025-11-09 17:015mo ago
Ethereum network gas fees drop to just 0.067 Gwei amid slowdown
The cheap network fees are a boon for traders but could signal long-term fundamental issues with Ethereum's revenue generation model.
41
Gas fees on the Ethereum layer-1 blockchain dropped to just 0.067 Gwei on Sunday, amid a lull in the crypto markets sparked by October’s historic market crash.
The average price for executing a swap on Ethereum is just $0.11, non-fungible token (NFT) sales carry a fee of $0.19, bridging a digital asset to another blockchain network will cost users $0.04, and onchain borrowing costs $0.09 at the time of this writing, according to Etherscan.
Ethereum network transaction fees hit a recent high of 15.9 Gwei on October 10, the day of the market flash crash that caused some altcoins to shed over 90% of their value within 24 hours.
However, by October 12, fees dropped back down to just 0.5 Gwei and mostly remained well below 1 throughout October and November.
Ethereum layer-1 gas prices over the last month. Source: EtherscanInvestors and traders may take advantage of the low transaction fees to execute onchain transactions on the base layer. However, analysts and crypto industry executives warn that the excessively low fees might spell trouble for the Ethereum ecosystem.
The Ethereum base layer has seen a loss of revenue since 2024During the 2021 bull run, transaction fees on the Ethereum layer-1 could cost users $150 or more during times of network congestion.
However, following the Ethereum Dencun upgrade in March 2024, which lowered transaction fees for Ethereum’s layer-2 scaling networks, fees contracted significantly, causing Ethereum’s revenue to decline by 99%.
Ethereum layer-1 network fees 2023-2025. Source: Token TerminalCritics say the low network fees are unsustainable for any blockchain network and present both financial and security challenges due to the lack of revenue to incentivize validators or miners to process transactions and secure the blockchain.
Because fees are responsive to user demand, low fees and revenues could also signal that users are moving away from a particular blockchain network.
Ethereum, in particular, has chosen a scaling strategy that relies on an ecosystem of separate layer-2 networks, which represents a double-edged sword, according to research from crypto exchange Binance.
While layer-2 networks allow Ethereum to scale and compete with newer, high-throughput chains, the Layer-2 networks are also cannibalizing revenue from the base layer, creating additional competition for Ethereum within its own ecosystem.
Magazine: How Ethereum treasury companies could spark ‘DeFi Summer 2.0’
2025-11-09 22:305mo ago
2025-11-09 17:155mo ago
‘Buckle Up'—Crypto Braced For ‘Stimulus Check' Price Shock As Trump Suddenly Sends Bitcoin Higher
Bitcoin has surged higher following its 20% plummet from its all-time high to under $100,000 (helped by Wall Street giant JPMorgan revealing a major bitcoin bet).
Sign up now for CryptoCodex—A free crypto newsletter that will get you ahead of the market
The bitcoin price has climbed to around $105,000 despite a nightmare scenario for the bitcoin price suddenly starting to come true that could spell disaster for the stock market.
Bitcoin’s rally comes as U.S. president Donald Trump promises a “tariff dividend” of at least $2,000 per person that’s been described as a “stimulus check”—something that helped power the Covid-era bitcoin boom.
Sign up now for the free CryptoCodex—A daily five-minute newsletter for traders, investors and the crypto-curious that will get you up to date and keep you ahead of the bitcoin and crypto market bull run
ForbesJPMorgan Reveals Huge Bitcoin Bet As It Predicts A $3.5 Trillion Price BoomBy Billy Bambrough
MORE FOR YOU
U.S. president Donald Trump has confirmed the government will be sending $2,000 stimulus checks—something that could help drive the bitcoin price higher.
Getty Images
"A dividend of at least $2,000 a person (not including high income people!) will be paid to everyone," Trump posted to his Truth Social account, adding those against his controversial trade tariffs are “fools” and the U.S. is are taking in “trillions of dollars and will soon begin paying down our enormous” $37 trillion debt.
The prospect of the U.S. government returning to sending payments directly to people has sparked speculation it could boost the bitcoin price and crypto market in the same way the Covid-era stimulus checks did.
"Crypto surges after President Trump announces $2,000 tariff "dividends" to be paid out to Americans," analysts with the The Kobeissi Letter posted to X alongside a screenshot of bitcoin and crypto prices rising. “Rate cuts + record highs + AI + stimulus checks. Buckle up.”
“‘Like’ if you’ll be buying bitcoin with your $2,000 Trump tariff stimulus,” Pete Rizzo, the former editor of Coindesk and a self proclaimed “bitcoin historian,” posted to X, adding: "Free bitcoin. It’s coming."
“Last time this happened, it started the 2021 crypto bull run where bitcoin pumped from $3,800 to $69,000,” another crypto influencer posted to X.
Sign up now for CryptoCodex—A free crypto newsletter that will get you ahead of the market
Forbes‘This Is Crazy’—Elon Musk Issues Serious $38 Trillion U.S. ‘Bankruptcy’ Warning Amid Growing Bitcoin Price Crash FearsBy Billy Bambrough
The bitcoin price has surged under the second Trump administration, though the bitcoin price has dropped back from recent highs since early October.
Forbes Digital Assets
Trump’s confirmation of the tariff dividend comes after he floated the idea of giving out checks of up to $2,000 in rebates derived from the revenues his tariff agenda has generated in early October.
"We’re thinking maybe $1,000 to $2,000, it would be great," Trump told One America News Network, adding his "number one" priority is “paying down debt, because people have allowed the debt to go crazy."
The U.S. debt pile has surged to almost $38 trillion this year, as a combination of huge Covid-era spending and higher interest rates contribute to what some fear could become a "crisis" for the U.S. dollar.
Trump’s global trade tariffs, which are facing legal challenges, earned the U.S. around $150 billion in the fiscal year that ended in September, according to Treasury Department data.
However, Trump said he expects tariffs to bring in over $1 trillion every year.
2025-11-09 21:295mo ago
2025-11-09 15:365mo ago
Rigetti EPS Preview: Betting on the Future of Quantum Computing
Key Takeaways Rigetti Computing is a leader in the red-hot quantum computing industry.Rigetti is one a mission to tackle humanity's most pressing problems. However, Rigetti remains primarily R&D focused presently.
What is Quantum Computing?What is quantum computing? Quantum computing is expected to be the next generation of computing, an improved version of a classical computer. Today’s computers store information as 0 (off) or 1 (on), flipping between each. Conversely, in a process called superposition, quantum computers can use both 0 and 1 at the simultaneously. An excellent metaphor for understanding quantum computing imagining a house where children are playing hide-and-go-seek. In this example, envision the children searching each room as today’s computers, with each room, nook, and cranny needing to be searched individually. Meanwhile, rather than checking each room individually, a quantum computer can search the entire house at once.
Quantum computers are not necessarily faster than traditional computers in every aspect. However, for certain complex problems. Quantum computers can solve problems that would take a conventional computer millions of years.
Rigetti Computing Company OverviewZacks Rank #3 (Hold) stock Rigetti Computing ((RGTI - Free Report) ) is a leader in the scorching-hot quantum computing industry group. Rigetti builds industry-leading “superconducting quantum chips” which can be used for finance, logistics, and scheduling applications. The company’s website states its mission as to “Build the world’s most powerful computers to help solve humanity’s most important and pressing problems.”
Rigetti Earnings Preview· When: Rigetti will report Q3 2025 earnings on Monday, November 10th, after the US stock market closes.
· Wall Street Expectations: Zacks Consensus Analyst Estimates suggest that revenue will be a tepid $2.39 million in Q3, while EPS will be $-0.05.
· EPS Track Record: RGTI has a mixed EPS track record. The company has matched Wall Street expectations twice, missed once, and has beaten once as a public company.
Image Source: Zacks Investment Research
· Implied Move: The options market suggests a post-eps move of ~14%.
Rigetti: What to Know about EPSRigetti management acknowledges that the company is still mainly in the R&D stage. In other words, unlike most companies, Rigetti will not be judged primarily by its earnings results relative to Wall Street expectations, but instead by news partnerships, technological advances, and forward-looking statements.
Rigetti Performance & Technical ViewOver the past year, investors have looked beyond Rigetti’s unproven earnings and sales track record and have instead bet on the future technology of quantum computing. RGTI has been a momentum trader’s dream, with shares soaring some 2,261% over the past year. After the last explosive thrust higher, RGTI shares are testing the rising 50-day moving average – an intermediate trend filter investors should be monitoring.
Image Source: TradingView
Bottom Line
Quantum computing promises to transform how complex problems are solved. As Q3 EPS approaches, Rigetti sits at the forefront of this next-generation technological revolution.
2025-11-09 21:295mo ago
2025-11-09 15:475mo ago
Gold vs Silver ETFs: GDX Offers Broader Mining Exposure Than SIL
VanEck Gold Miners ETF offers broader gold mining exposure and lower costs, while Global X Silver Miners ETF focuses on silver miners with a higher yield.
The Global X Silver Miners ETF (SIL +2.71%) and the VanEck Gold Miners ETF (GDX +2.53%) both target the mining sector, but with distinct emphases: SIL tracks global silver mining companies, while GDX invests in firms primarily engaged in gold mining. This comparison highlights key differences in cost, returns, risk, and portfolio composition to help clarify which may appeal depending on your objectives.
Snapshot (cost & size)MetricSILGDXIssuerGlobal XVanEckExpense ratio0.65%0.51%1-yr return (as of Oct. 27, 2025)61.0%69.0%Dividend yield1.3%0.6%AUM$3.5 billion$21.2 billionBeta measures price volatility, with figures based on available data.
GDX is more affordable with a lower expense ratio, while SIL stands out for its higher payout. For cost-focused investors, the difference is modest, but yield-oriented buyers may notice the gap.
Performance & risk comparisonMetricSILGDXMax drawdown (5 y)-55.93%-46.52%Growth of $1,000 over 5 years$1,576$1,914What's insideAt 19.5 years old, VanEck Gold Miners ETF is fully invested in the basic materials sector, with 52 holdings as of October 2025. Its largest positions include Agnico Eagle Mines Ltd (AEM +1.33%), Newmont Corp (NEM +1.04%), and Barrick Mining Corp (B +1.66%). The fund provides broad access to global gold mining companies.
Global X Silver Miners ETF, by contrast, concentrates on the silver mining niche. Its portfolio is 100% basic materials, with 38 holdings. Top positions include Wheaton Precious (WPM +2.89%), Pan American Silver Corp (PAAS +2.90%), and Coeur Mining Inc (CDE +1.73%). SIL’s focus makes it more specialized within the silver industry.
For more guidance on ETF investing, check out the full guide at this link.
Foolish takePrices of both gold and silver have surged in 2025, rising more than 50% each due to geopolitical tensions, economic uncertainly, and central bank buying. Gold and silver are considered as safe-haven assets and a hedge against inflation and uncertainty. For silver, a tight global supply has also been a key price driver since silver is used extensively in industries like electronics, solar panels, and electric vehicles. 60% of global demand for silver comes from the industrials sector.
Investors seeking exposure to gold and silver have plenty of investment options, including buying bullion, gold and silver stocks, futures, or gold and silver ETFs like the VanEck Gold Miners ETF and the Global X Silver Miners ETF. These ETFs invest in a basket of gold and silver mining stocks worldwide, respectively. Since the fortunes of mining companies are tied closely to metal prices, these ETFs provide exposure to metal prices without the risk of buying and holding physical bullion.
GDX data by YCharts
Investors may choose between the two ETFs depending on whether they want to bet on silver or gold. The Global X Silver Miners ETF, however, is a pure-play silver mining ETF. The VanEck Gold Miners ETF owns shares in large and mid-tier gold miners as well as some silver producers, including Wheaton Precious and Pan American Silver.
So, the VanEck Gold Miners ETF is slightly more diversified and also cheaper, with a lower expense ratio, than the Global X Silver Miners ETF. GDX has also historically outperformed SIL, although rising demand for silver could help SIL close the gap in the coming years.
GlossaryETF (Exchange-Traded Fund): An investment fund traded on stock exchanges, holding a basket of assets like stocks or bonds.
Expense ratio: The annual fee, as a percentage of assets, that a fund charges its investors.
Dividend yield: The annual dividends paid by an investment, shown as a percentage of its current price.
Beta: A measure of an investment's volatility compared to the overall market; higher beta means greater price swings.
AUM (Assets Under Management): The total market value of assets managed by a fund or investment company.
Max drawdown: The largest percentage drop from a fund’s peak value to its lowest point over a specific period.
Holdings: The individual securities or assets owned within a fund or portfolio.
Basic materials sector: Industry segment focused on companies producing raw materials, such as metals, mining, and chemicals.
2025-11-09 21:295mo ago
2025-11-09 16:005mo ago
AppLovin Beats Earnings, but the SEC Investigation Is the Real Story Investors Should Be Watching
The ongoing probe into its data gathering practices is casting a dark cloud over its stock.
AppLovin (APP 0.24%) posted its third-quarter earnings report on Nov. 5. The adtech company's revenue surged 68% year over year to $1.41 billion and exceeded analysts' expectations by $70 million. Its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) jumped 90% to $1.16 billion, while its earnings per share (EPS) rose 96% to $2.45 and cleared the consensus forecast by $0.06.
Those year-over-year growth rates notably exclude its mobile gaming business, which it sold to Tripledot Studios this July, from both periods. On a sequential basis, it expects its revenue to rise 12% to 14% in the fourth quarter as its adjusted EBITDA increases 11% to 14%.
Image source: Getty Images.
That outlook also surpassed analysts' estimates, but the ongoing Securities and Exchange Commission (SEC) probe of its data collection practices likely capped its post-earnings gains. Let's see how that investigation might impact AppLovin's business and weigh down its stock.
How did AppLovin evolve over the past three years?
AppLovin was originally a mobile game publisher. But in 2022, it acquired the mobile adtech company MoPub and the connected TV advertising company Wurl to expand its digital advertising business. In 2023, it launched its artificial intelligence (AI)-powered Axon ad discovery platform. As it helped more mobile developers monetize their apps, its growth accelerated.
AppLovin subsequently expanded its advertising ecosystem into non-gaming markets (like e-commerce marketplaces and connected TV services), and launched a new self-service platform that allowed advertisers to manage their own ad campaigns. That AI-driven advertising business became its core growth engine and offset the sluggish growth of its legacy gaming business. That's why it sold its entire mobile gaming business for $400 million in cash last year.
Today's Change
(
-0.24
%) $
-1.48
Current Price
$
619.88
It even placed a bid to buy TikTok's international business from ByteDance earlier this year, but it could struggle to outbid bigger potential suitors like Amazon, Microsoft, and Oracle (which already hosts TikTok's U.S. user data). The SEC probe could also hurt its chances of winning that bid.
Why is the SEC investigating AppLovin?
Over the past year, several prolific short-sellers claimed AppLovin's data collection strategies violated app store policies. They accused it of impermissibly pulling user IDs from other apps run by Alphabet's Google, Meta Platforms, Snap, TikTok, Reddit, and others to craft its own targeted ads. Most of those allegations targeted its AI-driven Axon platform.
AppLovin denied those allegations, but its stock stumbled in early October after Bloomberg claimed the SEC was probing its data collection services. In its latest 10-Q filing, it admitted that if those claims are successful, its "business, financial condition, and results of operations could be adversely affected." It warns that even if those claims are eventually resolved in its favor, the costs of defending itself "could divert the resources of our management and our board of directors" and throttle its growth.
Why do investors need to keep an eye on the SEC probe?
From 2024 to 2027, analysts still expect AppLovin's revenue and adjusted EBITDA to grow at a CAGR of 27% and 42%, respectively. Most of that growth should be driven by Axon's AI-powered targeted ads and its self-service advertising platform. With an enterprise value of $209 billion, AppLovin trades at 28 times next year's revenue and 34 times its adjusted EBITDA. Those valuations seem reasonable, but they're pinned to the expectations that Axon's AI-powered adtech platform will expand and evolve.
But if the SEC probe escalates into a full-blown lawsuit, AppLovin's valuations will likely decline as the regulators cast dark clouds over Axon's future. AppLovin's insiders sold more than 4 times as many shares as they sold over the past three months, and that chilly insider sentiment suggests that its shares could remain under pressure for the foreseeable future. AppLovin could still have a lot of long-term growth potential, but investors shouldn't go all-in on its stock until it fully addresses these issues. That said, it might still be worth nibbling on as a speculative play on the secular expansion of the AI-powered adtech market.
Leo Sun has positions in Amazon and Meta Platforms. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Microsoft, and Oracle. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
2025-11-09 21:295mo ago
2025-11-09 16:005mo ago
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many driven by delayed diagnosis or treatment.
Through this initiative, the American Heart Association is establishing valve disease as a critical focus area for the organization and aligning patient education, clinician training, systems of care and quality improvement to drive measurable impact.
“For more than 65 years, Edwards has been dedicated to transforming care for patients with structural heart disease by developing breakthrough therapies. We produce world-class evidence demonstrating durable and differentiated patient outcomes, and support physician training and education to understand the severity of valvular heart disease and to close gaps in diagnosis and treatment,” said Dan Lippis, corporate vice president, transcatheter aortic valve replacement. “Yet despite decades of innovation, evidence and education on the undeniable health benefits of aortic stenosis treatment, and corresponding economic benefits to healthcare ecosystems, there continues to be serious inadequacy in treatment access. That’s why there is a meaningful opportunity now for this groundbreaking initiative with the American Heart Association. It reflects our shared urgency and builds on our legacy, accelerating progress to help clinicians recognize symptoms earlier, treat patients faster and save more lives.”
The Heart Valve Initiative will expand the reach of Target: Aortic Stenosis, an American Heart Association program also founded through Edwards’ sponsorship. Over the next five years, the initiative will:
Improve adherence to guideline-based care, beginning with aortic stenosis
Expand data collection to include asymptomatic and moderate AS cases
Establish a heart valve certification program for hospitals
Advance public reporting and hospital recognition
Provide multimedia education for clinicians and patients
Launch a national awareness campaign to support informed care decisions
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as “may,” “might,” “believe,” “will,” “expect,” “project,” “estimate,” “should,” “anticipate,” “plan,” “goal,” “continue,” “seek,” “intend,” “optimistic,” “aspire,” “confident” and other forms of these words and include, but are not limited to, statements made by Mr. Lippis and statements regarding the production of world-class evidence, durable and differentiated patient outcomes, the results of the AHA heart valve initiative, including improving adherence to guideline-based care, expand data collection with respect to asymptomatic and moderate AS cases, establish heart valve certification programs for hospitals, advance public reporting and hospital recognition, provide multimedia education to stakeholders and launch a national awareness campaign and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
2025-11-09 21:295mo ago
2025-11-09 16:105mo ago
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 51.6% to $24.8 million in the third quarter of 2025 from $16.4 million in the third quarter of 2024Total Company Adjusted EBITDA(1) was $84.9 million in the third quarter of 2025 as compared with $73.7 million in the third quarter of 2024, an increase of 15.2%; Digital Health reportable segment Adjusted EBITDA(1) increased 6.9% to $3.5 million in the third quarter of 2025 from $3.2 million in the third quarter of 2024Total Company Adjusted EBITDA(1) margins increased by 26 bps to 16.2% in the third quarter of 2025 as compared with 16.0% in the third quarter of 2024Adjusting for unusual or one-time items in the quarter, Adjusted Diluted Earnings Per Share(3) was $0.20 for the third quarter of 2025; This compares with Adjusted Diluted Earnings Per Share(3) of $0.18 for the third quarter of 2024In the third quarter of 2025, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 13.0% and same-center advanced imaging procedural volumes increased 9.9% as compared with the third quarter of 2024As of September 30, 2025, we had a cash balance of $804.7 million and Net Debt to Adjusted EBITDA(1) ratio of approximately 1.0xRadNet revises full-year 2025 guidance levels to increase Imaging Center Revenue and Adjusted EBITDA(1) ranges and Digital Health Revenue ranges
LOS ANGELES, Nov. 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2025.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “The business continues to demonstrate strong growth and record results in each of the Imaging Center and Digital Health reportable operating segments. Total Company Revenue grew 13.4% and Adjusted EBITDA(1) grew 15.2% as compared with last year’s third quarter, resulting in Adjusted EBITDA(1) margin expansion of 26 basis points. Contributing to the achievement of these results were the continued focus on creating capacity at existing centers, new center openings, ongoing business mix shift towards advanced imaging, tuck-in acquisitions, increased reimbursement from commercial and capitated payors, the expansion of health system joint ventures and an acceleration of Digital Health Revenue growth.”
Dr. Berger continued, “During the quarter, we experienced strong aggregate and same-center advanced imaging procedural volume growth. Aggregate advanced imaging procedural volumes increased 13.0% and same-center advanced imaging grew 9.9% relative to last year’s third quarter. As a result, RadNet’s advanced imaging business mix increased 153 basis points from last year’s third quarter, from 26.7% of all procedures in the third quarter of 2024 to 28.2% in the third quarter of 2025.”
“Given the positive trends we are experiencing in virtually all aspects of the business and the strong financial performance of the third quarter, we are revising upwards certain guidance levels in anticipation of financial results that we believe will exceed both original expectations and the adjustments we made to the guidance ranges upon releasing first and second quarter 2025 results. We have increased 2025 Imaging Center guidance ranges for Revenue and Adjusted EBITDA(1) and have raised Revenue Guidance for the Digital Health operating segment,” added Dr. Berger.
“RadNet’s balance sheet remains strong. At third quarter end, we had a cash balance of $804.7 million and a leverage ratio of Net Debt to Adjusted EBITDA(1) of approximately 1.0. This liquidity position provides the financial flexibility to continue to drive organic growth and to pursue attractive strategic acquisitions of both imaging centers and digital health targets,” concluded Dr. Berger.
Third Quarter Financial Results
For the third quarter of 2025, RadNet reported Total Company Revenue of $522.9 million and Adjusted EBITDA(1) of $84.9 million. Revenue increased $61.7 million (or 13.4%) and Adjusted EBITDA(1) increased $11.2 million (or 15.2%) as compared with the third quarter of 2024.
For the third quarter of 2025, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $24.8 million and Adjusted EBITDA(1) of $3.5 million. Revenue increased $8.4 million (or 51.6%) and Adjusted EBITDA(1) increased $223,000 (or 6.9%) as compared with the third quarter of 2024.
Unadjusted for unusual or one-time items impacting the third quarter, Total Company Net Income for the third quarter of 2025 was $5.4 million as compared with a Total Company Net Income of $3.2 million for the third quarter of 2024. Fully diluted Net Income Per Share for the third quarter of 2025 was $0.07, compared with a fully diluted Net Income Per Share of $0.04 in the third quarter of 2024, based upon a weighted average number of diluted shares outstanding of 77.4 million shares in 2025 and 75.2 million shares in 2024.
There were a number of unusual or one-time items impacting the third quarter including: $2.6 million of non-cash loss from interest rate swaps; $1.4 million in severance expense related to cost-savings initiatives; $621,000 expense related to leases for de novo facilities under construction that have yet to open their operations; $5.5 million of non-capitalized research and development expenses related to the DeepHealth Cloud OS and AI solutions; $2.1 million of acquisition transaction costs; and $2.8 million of lease abandonment charges. Adjusting for the above items, Total Company Adjusted Earnings(3) was $15.8 million and diluted Adjusted Earnings Per Share(3) was $0.20 during the third quarter of 2025. This compares with Total Company Adjusted Earnings(3) of $13.3 million and diluted Adjusted Earnings Per Share(3) of $0.18 during the third quarter of 2024.
For the third quarter of 2025, as compared with the prior year’s third quarter, MRI volume increased 14.8%, CT volume increased 9.4% and PET/CT volume increased 21.1%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 6.9% over the prior year’s third quarter. On a same-center basis, including only those centers which were part of RadNet for both the third quarters of 2025 and 2024, MRI volume increased 11.5%, CT volume increased 6.7% and PET/CT volume increased 14.9%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 4.9% over the prior year’s same quarter
Nine Month Financial Results
For the first nine months of 2025, RadNet reported Total Company Revenue of $1,492.5 million and Adjusted EBITDA(1) of $212.5 million. Revenue increased $139.9 million (or 10.3%) and Adjusted EBITDA(1) increased $8.1 million (or 3.9%) as compared with the first nine months of 2024.
For the first nine months of 2025, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $64.8 million and Adjusted EBITDA(1) of $10.6 million. Revenue increased $17.9 million (or 38.2%) and Adjusted EBITDA(1) increased $548,000 (or 5.5%) as compared with the first nine months of 2024.
Unadjusted for one-time or unusual items, Total Company Net Loss for the first nine months of 2025 was $18.1 million as compared with a Total Company Net Loss of $2.6 million for the first nine months of 2024. Fully diluted Net Loss Per Share for the nine month period of 2025 was $(0.24), compared with a Net Loss Per Share of $(0.04) in the nine month period of 2024, based upon a weighted average number of diluted shares outstanding of 74.7 million shares in 2025 and 72.6 million shares in 2024.
2024 Guidance Update
RadNet amends its previously announced guidance levels as follows:
Imaging Center Segment Original Guidance RangeRevised Guidance Range After Q1 ResultsRevised Guidance Range After Q2 ResultsRevised Guidance Range After Q3 ResultsTotal Net Revenue$1,825 - $1,875 million$1,835 - $1,885 million$1,850 - $1,900 million$1,900 - $1,930 millionAdjusted EBITDA(1)$265 - $273 million$268 - $276 million$271 - $279 million$276 - $284 millionCapital Expenditures(a)$140 - $150 million$145 - $155 million$152 - $162 million$157 - $167 millionCash Interest Expense(b)$35 - $40 million$35 - $40 million$35 - $40 million$31 - $36 millionFree Cash Flow(2)$70 - $80 million$70 - $80 million$70 - $80 million$70 - $80 million (a) Net of proceeds from the sale of equipment and New Jersey Imaging Network capital expenditures.
(b) Net of payments received from counterparties on interest rate swaps and interest income from our cash balance recorded in Other Income.
Digital Health Segment Original
Guidance RangeRevised
Guidance Range After
Q1 ResultsRevised
Guidance Range After
Q2 ResultsRevised
Guidance Range After
Q3 Results Total Net Revenue (inclusive of intersegment revenue) $80 - $90 million$80 - $90 million$80 - $90 million$85 - $95 million Adjusted EBITDA(1) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $15 - $17 million$15 - $17 million$15 - $17 million$15 - $17 million Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $16 - $18 million$16 - $18 million$17 - $19 million$18 - $20 million Capital Expenditures $3 - $5 million$3 - $5 million$2 - $4 million$3 - $5 million Free Cash Flow(2) Before Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $11 - $13 million$11 - $13 million$11 - $13 million$10 - $12 million Free Cash Flow(2) After Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI $(5) - $(8) million$(5) - $(8) million$(5) - $(8) million$(6) - $(9) million
Dr. Berger explained, “Based upon the consistent outperformance of the first three quarters of this year relative to our projections, we have increased guidance ranges of our core Imaging Center reporting segment for Revenue and Adjusted EBITDA(1). With respect to the Digital Health reportable segment, we updated the Revenue guidance range upwards, due in part to the contribution of iCAD Revenue beginning in mid-July. We have kept our Digital Health Adjusted EBITDA(1) guidance range unchanged.”
Conference Call for Tomorrow
Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter 2025 results on Monday, November 10th, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Conference Call Details:
Date: Monday, November 10, 2025
Time: 10:30 a.m. Eastern Time
Dial-In Number: 844-826-3035
International Dial-In Number: 412-317-5195
It is recommended that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1740003&tp_key=5e6a1fc906 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10204112.
About RadNet, Inc.
RadNet, Inc. is a leading provider of outpatient diagnostic imaging services in the United States, with a network of 407 owned and operated imaging centers. The company’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. For more information, visit www.radnet.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:
the availability and terms of capital to fund our business;our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms;changes in general economic conditions nationally and regionally in the markets in which we operate;the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities;our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so;our ability to acquire, develop, implement and monetize technology, digital health initiatives, artificial intelligence algorithms and applications;volatility in interest and exchange rates, or credit markets;the adequacy of our cash flow and earnings to fund our current and future operations;changes in service mix, revenue mix and procedure volumes;delays in receiving payments for services provided;increased bankruptcies among our partner physicians or joint venture partners;the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act;the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business;closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers’ abilities to deliver supplies needed in our facilities;the occurrence of hostilities, political instability or catastrophic events;the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; andnoncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.
Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.
Regulation G: GAAP and Non-GAAP Financial Information
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company’s financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
CONTACTS:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer
RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) September 30, 2025 December 31, 2024 (unaudited) ASSETS CURRENT ASSETS Cash and Cash equivalents$804,716 $740,020 Accounts receivable 210,548 185,821 Due from affiliates 12,362 41,869 Prepaid expenses and other current assets 50,151 51,542 Total current assets 1,077,777 1,019,252 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property and equipment, net 780,502 694,791 Operating lease right-of-use assets 675,330 639,740 Total property, plant, equipment and right-of-use assets 1,455,832 1,334,531 OTHER ASSETS Goodwill 827,532 710,663 Other intangible assets 124,912 81,351 Deferred financing costs 1,829 2,265 Investment in joint ventures 129,127 104,057 Deferred tax assets, net 5,261 - Deposits and other 43,009 34,571 Total Assets$3,665,279 $3,286,690 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other$419,207 $351,464 Due to affiliates 61,748 43,650 Deferred revenue 8,170 3,288 Current operating lease liability 60,335 56,618 Current portion of notes payable 25,454 24,692 Total current liabilities 574,914 479,712 LONG-TERM LIABILITIES Long-term operating lease liability 690,935 655,979 Notes payable, net of current portion 1,070,886 991,574 Deferred tax liability, net - 22,230 Other non-current liabilities 14,585 3,785 Total liabilities 2,351,320 2,153,280 EQUITY RadNet, Inc. stockholders' equity: Common stock - $0.0001 value, 200,000,000 shares authorized; 77,032,154 and 74,036,993 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 8 7 Additional paid-in-capital 1,147,402 988,147 Accumulated other comprehensive loss 5,970 (9,061)Accumulated deficit (94,840) (76,785)Total RadNet, Inc.'s Stockholders' equity: 1,058,540 902,308 Noncontrolling interests 255,419 231,102 Total Equity 1,313,959 1,133,410 Total liabilities and equity$3,665,279 $3,286,690 RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENT OF OPERATIONS(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)(unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025
2024
2025
2024
REVENUE Service fee revenue$491,426 $427,579 $1,398,838 $1,247,513 Revenue under capitation arrangements 31,443 33,563 93,660 105,050 Total service revenue 522,869 461,142 1,492,498 1,352,563 OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 450,379 391,800 1,332,944 1,169,113 Lease abandonment charges 2,819 - 8,330 - Depreciation and amortization 39,799 34,979 111,275 101,822 Loss (gain) on sale and disposal of equipment and other 1,042 148 3,168 735 Severance costs 1,441 304 2,614 797 Total operating expenses 495,480 427,231 1,458,331 1,272,467 INCOME (LOSS) FROM OPERATIONS 27,389 33,911 34,167 80,096 OTHER INCOME AND EXPENSES Interest expense 17,355 19,427 51,783 61,776 Equity in earnings of joint ventures (3,567) (3,595) (10,522) (11,308)Non-cash change in fair value of interest rate hedge 2,371 6,755 6,433 7,429 Debt restructuring and extinguishment expenses - 147 - 8,909 Other (income) expenses (9,044) (5,414) (24,520) (16,248)Total other (income) expenses 7,115 17,320 23,174 50,558 INCOME (LOSS) BEFORE INCOME TAXES 20,274 16,591 10,993 29,538 Provision for income taxes (6,385) (4,335) (3,807) (4,927)NET INCOME (LOSS) 13,889 12,256 7,186 24,611 Net income (loss) attributable to noncontrolling interests 8,472 9,047 25,241 27,163 NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$5,417 $3,209 $(18,055) $(2,552) BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.07 $0.04 $(0.24) $(0.04) DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.07 $0.04 $(0.24) $(0.04)WEIGHTED AVERAGE SHARES OUTSTANDING Basic 75,950,350 73,494,709 74,703,658 72,587,321 Diluted 77,388,477 75,165,435 74,703,658 72,587,321 RADNET, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS)(unaudited) Nine Months Ended September 30, 2025
2024
CASH FLOWS FROM OPERATING ACTIVITIES Net income$7,186 $24,611 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 111,275 101,822 Noncash operating lease expense 44,605 45,516 Equity in earnings of joint ventures, net of dividends (4,590) (10,308)Amortization of deferred financing costs and loan discount 2,242 2,336 Loss on sale and disposal of equipment 3,168 735 Loss on extinguishment of debt - 2,080 Lease abandonment charges 8,330 - Amortization of cash flow hedge 2,273 8,242 Non-cash change in fair value of interest rate swap 6,433 7,429 Stock-based compensation 46,276 21,368 Loss on impairment - 1,200 Change in fair value of contingent consideration - 1,974 Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Accounts receivable (20,476) (35,369)Other current assets 2,093 4,738 Other assets (2,764) (7,388)Deferred taxes 2 4,834 Operating leases (48,760) (40,497)Deferred revenue 3,934 (255)Accounts payable, accrued expenses and other 53,429 57,426 Net cash provided by operating activities 214,656 190,494 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities and other acquisitions, net of cash acquired (66,464) (37,748)Purchase of property and equipment and other (162,221) (145,164)Proceeds from sale of equipment 75 151 Equity contributions in existing and purchase of interest in joint ventures (4,147) (1,496)Collection of notes receivable 2,832 - Net cash used in investing activities (229,925) (184,257)CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on notes and leases payable (5,229) (4,296)Payments on Term Loan Debt (15,504) (688,375)Proceeds from issuance of new debt, net of issuing costs 99,001 863,815 Purchase of noncontrolling interests by third party 2,389 7,569 Payments on contingent consideration and holdbacks - (3,614)Distributions paid to noncontrolling interests (3,313) (2,423)Proceeds from sale of economic interests in majority owned subsidiary, net of taxes - 8,641 Proceeds from issuance of common stock - 218,385 Proceeds from issuance of common stock upon exercise of options 2,258 367 Net cash provided by financing activities 79,602 400,069 EFFECT OF EXCHANGE RATE CHANGES ON CASH 363 40 NET INCREASE IN CASH AND CASH EQUIVALENTS 64,696 406,346 CASH AND CASH EQUIVALENTS, beginning of period 740,020 342,570 CASH AND CASH EQUIVALENTS, end of period 804,716 748,916 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for interest$53,679 $57,227 Cash paid during the period for income taxes$3,480 $2,202 RADNET, INC. AND SUBSIDIARIESRECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(IN THOUSANDS) Three Months Ended September 30, Nine Months Ended September 30, 2025
2024
2025
2024
Net income (loss) attributable to RadNet, Inc. common stockholders$5,417 $3,209 $(18,055) $(2,552)Income taxes 6,385 4,335 3,807 4,927 Interest expense 17,355 19,427 51,783 61,776 Severance costs 1,441 304 2,614 797 Depreciation and amortization 39,799 34,979 111,275 101,822 Non-cash employee stock-based compensation 9,041 4,723 46,276 21,369 Loss (gain) on sale and disposal of equipment and other 1,042 148 3,168 735 Non-cash change in fair value of interest rate hedge 2,371 6,755 6,433 7,429 Other expenses (income) (9,044) (5,414) (24,520) (16,248)Non-Capitalized R&D - DeepHealth Cloud OS & Generative AI 5,486 3,345 13,835 9,977 Lease abandonment charges 2,819 - 8,330 - Loss (gain) on extinguishment of debt and related expenses - 147 - 8,909 Non-cash change to contingent consideration - - - 1,974 Non-operational rent expenses 621 1,287 2,459 3,119 Acquisition transaction costs 2,136 417 5,109 417 Adjusted EBITDA - RadNet, Inc.$84,869 $73,662 $212,514 $204,451 NOTE Adjusted EBITDA - Imaging Center Segment 81,417 70,433 201,948 194,433 Adjusted EBITDA - Digital Health Segment 3,452 3,229 10,566 10,018 PAYMENTS BY PAYOR CLASS Third Quarter 2025
Commercial Insurance 57.3%Medicare 23.6%Capitation 6.0%Medicaid 2.6%Workers Compensation/Personal Injury 2.2%Other* 8.4%Total 100.0% * Includes management fee, teleradiology and Digital Health financial reporting unit revenue. RADNET PAYMENTS BY MODALITY Third Quarter Full Year Full Year Full Year 2025
2024
2023
2022
MRI 38.4% 37.1% 36.8% 36.8%CT 15.4% 15.9% 16.8% 17.5%PET/CT 8.8% 7.2% 6.4% 5.8%X-ray 5.4% 6.0% 6.5% 6.7%Ultrasound 13.4% 13.6% 12.9% 12.6%Mammography 15.2% 16.4% 16.0% 15.3%Nuclear Medicine 0.8% 1.0% 0.8% 0.9%Other 2.5% 2.7% 3.9% 4.5% 100.0% 100.0% 100.0% 100.0% PROCEDURES BY MODALITY* Third Quarter Third Quarter 2025 2024 MRI 512,861 446,596CT 290,975 265,874PET/CT 22,817 18,844Nuclear Medicine 8,965 9,282Ultrasound 705,347 650,322Mammography 496,465 484,357X-ray and Other 889,888 862,732 Total 2,927,318 2,738,007 * Volumes include wholly owned and joint venture centers. RADNET, INC. AND SUBSIDIARIESSCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE(3)(IN THOUSANDS EXCEPT SHARE DATA)(unaudited) Three Months Ended September 30, September 30, 2025
2024
NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$5,417 $3,209 Non-cash impact of cash flow hedges (i) 2,587 8,111 Severance costs 1,441 304 Non-operational rent expenses (iii) 621 1,287 Non-capitalized R&D - DeepHealth cloud OS & generative AI 5,486 3,345 Acquisition transaction costs 2,136 417 Debt amendment fee - 147 Lease abandonment charges 2,819 - Total adjustments - loss (gain) 15,090 13,611 Subtract tax impact of Adjustments (ii) (4,753) (3,552) Tax effected impact of adjustments 10,337 10,059 TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS 10,337 10,059 ADJUSTED NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS 15,754 13,268 WEIGHTED AVERAGE SHARES OUTSTANDING Diluted 77,388,477 75,165,435 ADJUSTED DILUTED NET INCOME PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS$0.20 $0.18 (i) Impact is the sum of (a) the loss in fair value of the hedges during the quarter of $2,371 in 2025 and loss of $6,755 in 2024 and (b) the amortization of the accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective of $216 in 2025 and $1,356 in 2024.
(ii) Tax effected using 31.5% blended federal and state effective tax rate for 2025 and 26.1% for 2024.
(iii) Represents rent expense associated with de novo sites under construction prior to them becoming operational.
Footnotes
(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
(2) As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest Expense. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.
Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
(3) The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company’s tax provision and any other non-recurring or unusual transactions recorded during the period.
Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
2025-11-09 21:295mo ago
2025-11-09 16:155mo ago
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular risk reduction; a pivotal moment that underscores the need for more effective, evidence-based approaches to residual CV risk.
“Data presented at AHA are the direct result of our continued investments in supporting our VASCEPA/VAZKEPA franchise and reaffirm our commitment to advancing the science of cardiovascular care and addressing the very real issue of residual risk in patients worldwide. Cardiovascular disease continues to be the leading cause of death globally, and far too many high-risk patients are in urgent need of protection now. That is why we remain committed to raising awareness among healthcare providers, payers, and patients about the importance of using FDA-approved therapies for cardiovascular risk reduction, such as VASCEPA® (icosapent ethyl)—proven to reduce cardiovascular events—on top of statin therapy in patients with elevated triglycerides,” said Steven Ketchum, Ph.D., EVP, President of R&D, and Chief Scientific Officer at Amarin. “The updated FDA labeling for fibrates is a critical development for clinicians seeking to reduce residual risk in their patients. The recent label update for fibrates - prompted by a citizen petition led by HealthyWomen - now clearly states that fibrates do not reduce cardiovascular risk when used in combination with statins based on the neutral PROMINENT trial safety and efficacy data where a fibrate was added to statins in patients with diabetes who had high triglycerides and low HDL-C. The revised indication limits fibrate use only to reduce triglyceride levels in adults with severe hypertriglyceridemia or for LDL-C reduction in adults with primary hyperlipidemia when statin therapy is not possible. We must continue to reinforce the message that fibrates offer no added cardiovascular benefit over statins and the importance of treating patient outcomes.”
“REDUCE-IT data continue to yield important insights into the clinical utility of icosapent ethyl and how it can reduce cardiovascular risk across diverse patient populations,” said Deepak L. Bhatt, MD, MPH, MBA, Director of the Mount Sinai Fuster Heart Hospital in New York. “The new REDUCE-IT post hoc analyses continue to support the primary outcomes datai,ii and allow us to further substantiate icosapent ethyl’s ability to reduce cardiovascular risk with or without aspirin use - an important evidence gap given the potential overlapping antiplatelet effects.iii In addition, the cardioprotective properties of icosapent ethyl are further supported by mechanistic insights into the anti-inflammatory and endothelial-protective effects of eicosapentaenoic acid.iv This important therapy has consistently demonstrated cardioprotective benefits across diverse patient populations, including those at high risk with a history of myocardial infarction or stroke, or an acute coronary syndrome population based on recent publications.v,vi,vii These findings further support the role of icosapent ethyl as a valuable option in comprehensive cardiovascular risk management.”
Key findings from the post hoc analysis are outlined below:
Efficacy of Icosapent Ethyl for Cardiovascular Risk Reduction by Aspirin Use in REDUCE-IT
A new analysis from the REDUCE-IT study reinforces the cardiovascular (CV) benefits of icosapent ethyl, a purified form of eicosapentaenoic acid, in patients with elevated triglycerides and controlled LDL-C who are at increased CV risk. The study explored outcomes among patients with and without concurrent aspirin use—an important consideration given potential overlapping antiplatelet effects.
Among 8,179 statin-treated participants, a cohort of 6,179 (75.5%) received aspirin at baseline. Icosapent ethyl significantly reduced major adverse CV events compared with placebo, with consistent benefits observed in both aspirin users and non-users. Among aspirin users, icosapent ethyl significantly reduced primary endpoint events (CV death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina) by 28% (P<0.0001), with absolute risk reduction (ARR) of 5.9% and number needed to treat (NNT) of 17. In this cohort, total (first plus subsequent) primary composite endpoint events were reduced by 36%, Rate Ratio (RR) 0.64 (95% CI: 0.56, 0.74); P<0.0001. Notably, among the subgroup of 4,867 aspirin users in the secondary prevention cohort, icosapent ethyl similarly reduced total primary endpoint events by 39%, RR 0.61 (95% CI: 0.53, 0.70); P<0.0001). The safety profile of icosapent ethyl in aspirin users was consistent with the overall study population.
The analysis showed that icosapent ethyl provides CV protection beyond standard therapy with statins and aspirin, without incremental safety concerns, addressing a key evidence gap and supporting the role of icosapent ethyl in comprehensive CV risk management.
About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD. The Icahn School of Medicine at Mount Sinai receives research funding from Amarin for Dr. Bhatt’s role as the Chair of REDUCE-IT.
About VASCEPA®/VAZKEPA® (icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty-five million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Finland, England/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria.
United States
Indications and Limitation of Use
VASCEPA is indicated:
As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease ordiabetes mellitus and two or more additional risk factors for cardiovascular disease. As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel, or warfarin.Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding. FULL U.S. FDA-APPROVED VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT WWW.VASCEPA.COM.
Europe
For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA® in Europe, please visit: https://www.ema.europa.eu/en/documents/product-information/vazkepa-epar-product-information_en.pdf
Globally, prescribing information varies; refer to the individual country product label for complete information.
Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about Amarin’s key achievements in 2024 and the potential impact and outlook for achievements in 2025 and beyond; Amarin’s 2025 financial outlook and cash position; Amarin’s overall efforts to expand access and reimbursement to VAZKEPA across global markets; expectations regarding potential strategic collaboration and licensing agreements with third parties, including our ability to attract additional collaborators, as well as our plans and strategies for entering into potential strategic collaboration and licensing agreements and the overall potential and future success of VASCEPA/VAZKEPA and Amarin that are based on the beliefs and assumptions and information currently available to Amarin. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s quarterly report on Form 10-Q for the period ending September 30, 2025 and annual report on Form 10-K for the fiscal year ended 2024. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Investors and others should note that Amarin communicates with its investors and the public using the company website (www.amarincorp.com), the investor relations website (www.amarincorp.com/investor-relations) including but not limited to investor presentations and investor FAQs, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investors.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Media Inquiries:
Tegan Berry
Amarin Corporation plc [email protected]
i Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, for the REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792
ii Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. J Am Coll Cardiol 2019;74(8):1159-1161. DOI: 10.1016/j.jacc.2019.06.043
iii Mourikis P, Benkhoff M, Wildeis L, et al. Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1-induced platelet reactivity. Sci Transl Med. 2025;17(799):eado0610. doi: 10.1126/scitranslmed.ado0610.
iv Sherratt SCR, Libby P, Dawoud H, et al. Eicosapentaenoic acid improves endothelial nitric oxide bioavailability via changes in protein expression during inflammation. J Am Heart Assoc. 2024;13(14):e034076. doi: 10.1161/JAHA.123.034076.
v Gurevitz C, Bhatt DL, Giugliano RP, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Lira Pineda A, Doyle RT, Jr, Giugliano G, Mason RP, Tardif J-C, Martens FMAC, Ballantyne CM, Budoff MJ, Gibson CM, on behalf of the REDUCE-IT Investigators. Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT. Eur J Prev Cardiol 2025. DOI: 10.1093/eurjpc/zwaf602.
vi Gaba P, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Jr., Granowitz C, Tardif JC, Giugliano RP, Martens F, Gibson CM, Ballantyne CM, on behalf of the REDUCE-IT Investigators. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. J Am Coll Cardiol 2022;79(17):1660-1671. DOI: 10.1016/j.jacc.2022.02.035
vii Sayah N, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Jiao L, Pineda AL, Doyle RT Jr, Tardif JC, Ballantyne CM, Steg PG. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. Eur Heart J. 2024 Apr 1;45(13):1173-1176. doi: 10.1093/eurheartj/ehad889. PMID: 38252107; PMCID: PMC10984562.
2025-11-09 21:295mo ago
2025-11-09 16:165mo ago
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.
So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
2025-11-09 20:295mo ago
2025-11-09 13:055mo ago
Will Berkshire Hathaway Succeed After Warren Buffett Leaves?
Berkshire Hathaway has been one of the ultimate plays in the stock market.
Berkshire Hathaway (BRK.B +1.30%) has long been synonymous with its legendary leader, Warren Buffett. The conglomerate recently received a downgrade from KBW, citing concerns over Buffett's exit, as well as problems in some of its key areas of business. Overall, I think that any pullback in the stock is a buying opportunity. To think that Warren Buffett has been the only one making decisions at Berkshire Hathaway seems a bit naive. His cohort is good at what they do. Moreover, the thing that gets ignored about Buffett's succession is how much money the Oracle of Omaha is leaving on the table for investment. Buffett has amassed a giant cash pile, which gives the company a great deal of maneuverability in the coming years in terms of investment options.
A downgrade rooted in succession anxiety
According to CNBC, KBW's downgrade reflects mounting worries about Berkshire's ability to sustain performance without Buffett's steady hand. The firm pointed to ongoing challenges in its core operating units, which include its railroad division and its insurance businesses. While the firm could certainly be correct that there are headwinds facing these areas of Berkshire's business, they aren't necessarily permanent, and they don't change the fundamental strength of Berkshire's diversified model.
A prime example here was the performance displayed in the third quarter. Despite concerns from KBW, Berkshire's most recent results, which came out on Saturday, imply good things. Berkshire reported a whopping 34% increase in operating profit within its wholly owned businesses. These include Berkshire's insurance businesses and railroads. One of the main areas of strength was insurance underwriting income. This key area for Berkshire saw income increase to $2.37 billion.
Image source: Getty Images.
Some seem to forget that Buffett hasn't been making decisions in a vacuum. His successors have been quietly shaping the company's operations for years. Greg Abel, Buffett's chosen heir for the CEO role, has overseen Berkshire's non-insurance operations since 2018. Abel has earned Buffett's trust and the trust of many inside the company. The idea that Berkshire's success vanishes the moment Buffett leaves seems a bit short-sighted.
The power of $381 billion
Perhaps the key element of Berkshire's future potential is its enormous cash pile -- now sitting at a record $381.6 billion. This war chest gives Berkshire virtually unmatched flexibility in deploying capital during market downturns or periods of economic stress. In fact, Buffett's own conservative approach to investing in recent years may be setting the stage for significant opportunity under new leadership.
That cash reserve is more than just a number -- it's a strategic weapon. Should markets experience a correction, Berkshire will be in an ideal position to make large, opportunistic acquisitions or buy distressed assets at attractive valuations.
I seriously doubt that Abel will act too quickly on this cash pile, but for long-term-oriented investors, it's hard to pass up a company that has so much "fresh powder" at its disposal. Buffett himself has preached a philosophy of focusing on buying "businesses" rather than stocks. To follow that mantra, it's not hard to invest in Berkshire. How many companies do you know that carry over $380 billion in buying power? For perspective, Berkshire has so much money in its hands that it could buy General Motors (GM +2.77%) almost six times over.
A slow moment for Berkshire
I'll admit this is a slow time for the stock. With Buffett leaving, investors might be less eager to pay that "Buffett premium" for his investing prowess, as evidenced in the conglomerate's stock performance so far in 2025, with only 5.86% gains. By comparison, simply being invested in the S&P 500 has created returns of 16.56%. This seems to be motivated by simple uncertainty. Change is hard, and it seems likely that investors will be critical of Greg Abel's new management for a little while. Still, I don't think these troubles warrant avoiding the stock if you have a long-term mindset.
Uncertainty often breeds fear. But Berkshire's strength has always been its structure: a collection of durable, cash-generating businesses led by disciplined capital allocators. Buffett's departure will undoubtedly mark the end of an era, but it doesn't mark the end of Berkshire's success story. With the capital at its disposal, and a cohort of investors that have learned from the greatest of all time, I think Berkshire has a bright future, and buying on weakness makes sense.
Vistra has been drawing lots of attention among utilities, especially after its recent 15% sell-off from an all-time high.
In a state known for its love of big things, Irving, Texas-based Vistra (VST +3.46%) fits right in.
Not only is the company one of the largest non-regulated power generators in North America, it's also a major player in the nuclear space (operating six reactors, licensed for 60 years) and a huge power producer supplying both the wholesale and retail electricity markets.
Another big thing about Vistra right now are its market returns, which currently rank it third best of 31 stocks in the Utilities Select Sector SPDR Fund (XLU +1.39%) with a 40% year-to-date gain through Nov. 3. That's more than double the performance of the sector and the broader S&P 500.
Image source: Getty Images.
And since the market lows in early April, Vistra's outperformance has been even wider, as its stock has essentially doubled in seven months, while gaining 750% over the past three years, and more than 1,000% in total returns since 2020.
Right place, right time
Part of Vistra's outsized growth has to do with market sentiment -- being in the right sector at the right time -- which is supported by the Utility Sector's 20% YTD gain, which ranks it second, behind only the Technology Select Sector ETF (XLK 0.35%).
Another big part of its advance has to do with the fact that as a so-called merchant generator, Vistra does not earn the typical regulated rates of return that come with the public utility commission oversight that its monopoly style peers face, but rather, can sell power at market prices, to both wholesale buyers as well as its own base of 5 million retail customers.
Today's Change
(
3.46
%) $
6.38
Current Price
$
191.00
Of course, free markets move up and down but at a time when demand for power is rising -- due in part to the surge in new artificial intelligence (AI) projects -- and new power supply is limited and slow to develop, the case for high prices is strong.
Risk vs. reward
Vistra investors do need to be aware of the unpredictability of regulatory risk and fluctuations in commodity prices related to fuel for its plants and wholesale electric prices. They also need to acknowledge interest rate risk, which is consistent with any capital-intensive industry that carries significant debt.
In addition, there's also the reality that Vistra is not cheap, with a forward price-to-earnings (P/E) ratio of 29 times and forward price-to-sales (P/S) ratio of 3.4 times expected results over the coming 12 months. Both of the figures land Vistra in the mid-80th percentile range, meaning those valuation metrics have only been higher about 15% of the time.
All in, Vistra's recent reality has not gone unnoticed and continues to enjoy the support of utility industry analysts, with 85% (17 of 20) who cover Vistra currently rating it a buy, with an average 12-month price of $225, implying about 20% upside from current levels.
Buy the dip?
Compared to the utility sector's 2.5% average yield, not to mention the group's top payout of 5% to 6%, Vistra's 0.5% dividend is tiny. Even so, Koyfin data shows the company has increased it for five consecutive years and, with a dividend payout ratio of just 20%, can easily afford to pay it -- and likely continue to increase it.
That said, Vistra investors have been more than compensated with triple-digit stock price gains over the past three to five years, and are not likely involved with it as an income play. Over the short-term, however, the past three months has seen Vistra's stock slide about 11% at a time when the utility sector rose 3.5% and the S&P 500 added about 8.5%. Investors looking and waiting for a good entry point should take note that shares of Vistra have fallen 15% since hitting an all-time high of $219 on Sept. 25.
Vistra will update investors on Thursday Nov. 6, when it reports its third-quarter earnings results.
2025-11-09 20:295mo ago
2025-11-09 13:155mo ago
Does Michael Burry of "The Big Short" Fame Know Something Wall Street Doesn't? He Just Made a Billion-Dollar Bet Against 2 Companies Driving the AI Boom.
Michael Burry has proven his ability to identify a bubble. Back in the early 2000s, the hedge fund manager considered trends in the U.S. housing market unsustainable -- and decided to short this market, betting on a decline.
Amid the subprime mortgage crisis that unfolded, he collected more than $700 million for his clients thanks to that move. And Burry gained additional fame when Hollywood told the story in The Big Short a few years later.
Since that time, investors have closely watched Burry's moves, as they recognize his strength in spotting clues that may not be noticed by everyone. And as illustrated by his bet against the housing market, Burry isn't afraid to go against the crowd.
All this means that Burry's latest move -- concerning one of today's fastest-growing markets -- is likely to attract investors' attention. I'm talking about artificial intelligence (AI), a market forecast to grow from the billions now to more than $2 trillion by the end of the decade. Burry recently bet against two companies driving the AI boom. Does he know something Wall Street doesn't?
Image source: Getty Images.
Michael Burry's 13F
So, let's jump right in and consider this top investor's latest moves, shown in his 13F filing with the U.S. Securities and Exchange Commission. These are filings managers of more than $100 million in equities must submit on a quarterly basis -- and this is great for the rest of us investors, as it offers us a glimpse into the strategy of some of the world's most successful money managers.
In the third quarter, Burry bought $186 million in put options on Nvidia (NVDA +0.03%) and $912 million in put options on Palantir Technologies (PLTR +1.66%) for his Scion Asset Management portfolio, totaling a more than $1 billion bet against these AI giants. A put option, allowing the holder to sell a particular stock at a specific price at a future date, is a bet that the stock price will fall.
This move is striking because Nvidia and Palantir both have generated tremendous earnings growth in recent quarters, thanks to demand for their AI products and services, and are known as key companies in this AI revolution. Nvidia, selling the world's top-performing AI chip, dominates that market, while Palantir offers software systems that allow customers to easily apply AI to their needs.
Today's Change
(
0.03
%) $
0.05
Current Price
$
188.13
Palantir's explosive growth
In the third quarter, Palantir delivered double-digit gains in revenue and strong profitability and increased forecasts across the board for the full year. Nvidia is expected to release quarterly earnings later this month, but it's reported record revenue and high profitability on sales recently. Palantir's and Nvidia's stock performance has reflected this success, with the shares climbing 2,200% and 1,200%, respectively, over the past three years.
In spite of these bright earnings reports, though, Burry's third-quarter moves suggest he expects both Palantir and Nvidia stock prices to decline. So, we might wonder: Does Burry know something Wall Street doesn't?
Is an AI bubble forming?
In recent weeks, investors have debated whether a bubble is forming or has formed in the AI market, and that's even weighed on stock performance during certain trading sessions. But tech companies' earnings so far have been strong, and forecasts for growth ahead are encouraging -- so, even if we see some declines in the near term, the long-term picture remains bright. And this means investors could win by holding onto quality companies, such as Nvidia and Palantir, for the long haul.
As for Burry's bet, it's important to keep a couple of things in mind. He made this move in the third quarter, and we don't know if he's maintained it in recent weeks -- we also don't know if this bet is a short-term or long-term one.
And Burry -- like any investor -- isn't always right. Back in 2023, he posted "sell" on X, then a couple of months later said that he had been wrong.
So, what does this mean for investors? Burry's move doesn't mean you should sell or avoid all AI stocks. Instead, at this time as valuations overall have climbed, it's a great idea to maintain positions in stocks -- in AI or other industries -- with solid long-term stories, ones that could withstand potential near-term turbulence and still generate growth in the years to come. And at the same time, ensure that your portfolio is well diversified.
Whether Burry is right or not, these moves should help you manage any short-term headwinds -- and win over the long run.
2025-11-09 20:295mo ago
2025-11-09 13:175mo ago
The iShares Bitcoin Trust ETF Grows to $88 Billion Handily Beating the VanEck Bitcoin ETF
VanEck Bitcoin ETF (HODL +2.88%) and iShares Bitcoin Trust ETF (IBIT +2.83%) both aim to track the price of Bitcoin (BTC +2.51%) as closely as possible, offering investors a straightforward way to access the cryptocurrency’s performance. This comparison breaks down their costs, returns, risks, and key characteristics to help clarify which may align better for investors with different priorities.
Snapshot (cost & size)MetricHODLIBITIssuerVanEckISharesExpense ratio0.20%0.25%AUM$2.0 billion$88.0 billionHODL is slightly more affordable, with a 0.20% expense ratio compared to IBIT’s 0.25% (as reported by Financial Modeling Prep). However, IBIT’s AUM is significantly larger.
What's insideIBIT’s primary holding is bitcoin, with small amounts of cash also included.—reflecting its goal to match bitcoin’s price performance. The fund is relatively new (1.8 years old) but has already reached $88.0 billion in AUM as of November 3, 2025, and its top holdings list includes only bitcoin and small amounts of cash. There are no embedded quirks or leverage resets to watch for.
HODL, from VanEck, is similarly straightforward with just one holding: bitcoin, accounting for 100% of assets. Sector breakdowns are not reported, but like the iShares Bitcoin Trust ETF, the VanEck Bitcoin ETF tracks the price of bitcoin passively and has no notable quirks or added complexity. Both funds are designed for pure bitcoin exposure, differing mainly in size, liquidity, and fee structure.
For more guidance on ETF investing, check out the full guide at this link.
Foolish takeExchange-traded funds with larger assets under management tend to offer lower expense ratios than smaller funds that can't employ economies of scale. That is not the case with these two Bitcoin ETFs. The VanEck Bitcoin ETF is waiving all sponsor fees for the first $2.5 billion of the trust's assets through Jan. 10, 2026.
As of Nov. 3, 2025, the VanEck Bitcoin ETF had a market value of $1.96 billion, so there's still time to scoop up shares of the ETF without paying any fees. After Jan. 10, the fund will charge a 0.2% fee. The iShares Bitcoin Trust ETF manages over $85.3 billion worth of Bitcoin but it has a relatively large 0.25% expense ratio.
Despite charging a larger fee, the iShares Bitcoin Trust ETF isn’t delivering a more impressive performance. During the 12 months ended Nov. 4, 2025, it rose by 45.16%. Over the same time frame, the VanEck Bitcoin ETF delivered a slightly better 45.47% return.
GlossaryETF (Exchange-Traded Fund): An investment fund traded on stock exchanges, holding assets like stocks or commodities.
Spot bitcoin exposure: Direct investment in bitcoin, aiming to match its current market price without using derivatives.
Assets Under Management (AUM): The total market value of assets that a fund manages on behalf of investors.
Expense ratio: The annual fee, as a percentage of assets, that a fund charges to cover operating costs.
Beta: A measure of a fund's volatility compared to the overall market; higher beta means greater risk and potential return.
Max drawdown: The largest percentage drop from a fund’s peak value to its lowest point over a specific period.
Liquidity: How easily an asset or fund can be bought or sold without affecting its price.
Passive tracking: A strategy where a fund aims to replicate the performance of a specific index or asset, rather than outperform it.
Leverage reset: The process of adjusting a leveraged fund’s exposure, typically daily, to maintain a set leverage ratio.
2025-11-09 20:295mo ago
2025-11-09 13:305mo ago
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events
November 09, 2025 13:30 ET
| Source:
Heartflow, Inc.
NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced late-breaking data from the FISH&CHIPS Study presented at the American Heart Association (AHA) Scientific Sessions 2025. The new data add to the robust and growing body of evidence supporting AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging* — the most clinically validated framework for actionable CAD care.
The retrospective analysis, which evaluated nearly 8,000 symptomatic patients from a cohort of the FISH&CHIPS Study, represents the largest validation to date of the Heartflow Plaque Staging framework based on total plaque volume (TPV) measurement.1
Key findings include:
Patients in the highest TPV stage experienced more than a 5x greater risk of major cardiovascular events compared with patients in the lowest stage (hazard ratio 5.10, p-value < 0.0001).Higher plaque volume stages were independently associated with significantly increased rates of cardiovascular death and myocardial infarction over a median 3.3 years of follow-up.Associations remained significant after adjustment for coronary stenosis, FFRCT values and cardiovascular risk factors.
“This study provides strong validation of TPV-based staging measured with Heartflow Plaque Analysis as a predictor of future heart attacks or cardiovascular death,” said Timothy Fairbairn, Ph.D., principal investigator for the FISH&CHIPS study, Liverpool Heart and Chest Hospital, and Associate Professor at the University of Liverpool, UK. “The ability to accurately measure plaque will enable cardiologists to better predict which patients are most at risk above the traditional risk factors, and thus personalize treatment, in order to prevent heart attacks or death in the future.”
The findings build on results from the DECIDE Registry presented at the Society of Cardiovascular Computed Tomography (SCCT) 2025 Annual Scientific Meeting in July. DECIDE data showed that Heartflow Plaque Analysis with Plaque Staging led to changes in medical management for more than half of patients, resulting in an average reduction in LDL cholesterol of 18.7 mg/dL at 90 days. These results indicate management changes guided by Heartflow Plaque Staging result in an expected 15% decrease in risk of a cardiac event.2,3,4
“We are demonstrating how AI-powered Heartflow Plaque Analysis with Heartflow Plaque Staging can fundamentally change the way we manage CAD,” said Campbell Rogers, M.D., F.A.C.C., Chief Medical Officer at Heartflow. “These latest findings show that by embedding plaque insights directly into the diagnostic pathway, we can help physicians make more confident decisions to guide personalized and precise treatment for their patients.”
*Heartflow Plaque Analysis is an FDA-cleared device. Heartflow Plaque Staging is an investigational-only framework, and its safety and effectiveness have not been reviewed by the FDA.
About Heartflow’s Technology and Research
Heartflow’s technology is redefining precision cardiovascular care through clinically-proven AI and the world’s largest coronary imaging dataset. Heartflow has been adopted by more than 1,400 institutions globally and continues to strengthen its commercial presence to make this cutting-edge solution more widely available to an increasingly diverse patient population. Backed by ACC/AHA guidelines and supported by more than 600 peer-reviewed publications, Heartflow has redefined how clinicians manage care for nearly 500,000 patients worldwide. Key benefits include:
Proprietary data pipeline: Built from more than 110 million annotated CTA images, Heartflow’s data foundation powers advanced AI models that deliver highly accurate, reproducible insights across diverse patient populations.Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world practice with reproducibility and accuracy, Heartflow’s coronary CTA image acceptance rates exceed 96%.Seamless clinical integration via upgraded workflow: Heartflow delivers final quality-reviewed analyses instantly upon order, enabling clinicians to move from diagnosis to decision without delay.Quality system, global security and patient-data integrity compliance: Heartflow meets or exceeds leading international standards, including HITRUST, SOC 2 Type 2, GDPR, HIPAA, CCPA, ISO 13485, and ISO 27001. About Heartflow, Inc.
Heartflow is transforming coronary artery disease from the world’s leading cause of death into a condition that can be detected early, diagnosed accurately, and managed for life. The Heartflow One platform uses AI to turn coronary CTA images into personalized 3D models of the heart, providing clinically meaningful, actionable insights into plaque location, volume, and composition and its effect on blood flow — all without invasive procedures. Discover how we’re shaping the future of cardiovascular care at heartflow.com.
Applied Materials provides the equipment that AI chipmakers need.
Artificial intelligence (AI) has been the primary driver of the current bull market.
AI is the theme that connects the "Magnificent Seven" companies. And their tremendous growth -- combined with investors' seemingly insatiable demand for AI-related stocks -- over the past decade has put the market cap of each of the seven above $1 trillion. As a result, the seven tech giants now account for 37% of the S&P 500's market cap.
But I would argue that none of the Magnificent Seven stocks is the one to own for the next decade of AI expansion.
Instead, you can make a strong argument that Applied Materials (AMAT 1.61%) will be that stock. The company doesn't make artificial intelligence chips like Nvidia and Advanced Micro Devices. And it doesn't provide AI services like Apple, Alphabet, or Microsoft.
Today's Change
(
-1.61
%) $
-3.76
Current Price
$
229.77
AI picks and shovels
But Applied Materials does make the systems used to produce most new chips and advanced displays globally. And that makes it the ultimate AI pick-and-shovel play.
Image source: Getty Images.
In fact, most of the world's largest semiconductor manufacturers are Applied Materials customers. That includes Nvidia, Intel, Samsung, Taiwan Semiconductor Manufacturing, Broadcom, ASML Holding, Micron Technologies, and Texas Instruments. And there are many, many more.
None of these companies can manufacture their chips without the material deposition, atomic etching, precision measurement, and packaging equipment that Applied Materials supplies. It is the largest U.S. manufacturer of semiconductor equipment.
The company's closest competitor is Lam Research, as both firms target the deposition and etch equipment categories. Applied Materials' semiconductor equipment market share was 17.4% in 2024, while Lam's was 13.1%. ASML Holding had the largest market share, at 20.2%, but it focuses on the high-end lithography market, so it doesn't fully overlap with the other two firms' target markets.
Trade risks
There are definitely risks related to geopolitical and trade tensions for Applied Materials. A little more than a third of the company's revenue comes from the Chinese market, so a U.S.-China trade war would be highly detrimental to Applied Materials' top and bottom lines. In fact, in the company's fiscal third-quarter results, it warned of potentially lower sales in Q4 due to uncertainties related to China.
As a result of ongoing trade issues, as well as uncertainty about trade policy out of the White House, short-term results for Applied Materials may be a bit rocky. Last month, the company said it expected the expansion of the U.S.'s restricted export list would subtract some $600 million from fiscal 2026 revenues. In addition, the memory chip industry tends to be cyclical.
And in October, the company announced planned layoffs of 4% of its 36,100 full-time employees, or about 1,400 people. It said that "automation, digitalization, and geographic shifts are redefining our workforce needs and skill requirements." It added that the cuts will make it more competitive and productive.
Massive upside potential
But those are largely short-term issues. Over the longer term, semiconductor sales are expected to explode. Deloitte forecasts that semiconductor sales will hit $697 billion this year, up 11% from 2024. It sees sales reaching $1 trillion by 2030 and doubling to $2 trillion by 2040.
Applied Materials will report its fiscal fourth quarter results next week, on Nov. 13. Analysts expect full fiscal 2025 revenue to rise 4% and earnings per share to grow 8.1%.
The stock is already up 48% this year (at the time of this writing) and 245% over the past five years, taking its market cap to about $192 billion. That's far smaller than the stratospheric market caps of the Magnificent Seven firms. But the upside for Applied Materials is hard to overestimate given the tremendous expected growth of semiconductor sales, much of it driven by artificial intelligence.
Matthew Benjamin has positions in Alphabet and Microsoft. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Alphabet, Apple, Applied Materials, Intel, Lam Research, Microsoft, Nvidia, Taiwan Semiconductor Manufacturing, and Texas Instruments. The Motley Fool recommends Broadcom and recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.
$125,000 Per Hour Grassroots Final Batch Velocity, in a $20B+ VC-Flooded 2025 Market
November 09, 2025 1:53 PM EST | Source: Krown Technologies LLC
Monroe, Louisiana--(Newsfile Corp. - November 9, 2025) - Krown Network, the quantum-secured, bootstrapped Layer 1 blockchain, sold out its final pre-sale batch of $500,000 in just over 4 hours - delivering a scorching $125,000 per hour fundraising velocity that surpasses industry legends.
This raise burst surpasses Ethereum's full 2014 ICO, which raised at a velocity of $18,162 per hour. Krown's speed eclipses it by seven times that rate in head-to-head final timeframes, while BTC was mined at a negligible value in 2009, gradually increasing to under 1,000 wallets by mid-2010, with no significant capital influx.
Ethereum's ICO was tainted with a 12% pre-mine for the founders and the foundation, fueling early concerns about centralization. Krown, by contrast, bootstrapped $3M with zero VC interference, echoing Bitcoin's grassroots purity while channeling Ethereum's visionary scale - all in a 2025 crypto VC market exploding past $20 billion year-to-date, where over 90% of Layer 1 funding hides behind private VC deals and vesting schedules.
Krown's traction extends beyond ETH and BTC. This final batch velocity outruns foundational ICOs like Cardano (16 months at ~$5,399/hour) and Fantom (3 months at ~$18,519/hour), proving bootstrapped innovation still thrives amid hype-driven projects and coins.
In a year where crypto startups raked in billions through centralized exchanges and VCs, Krown's community-fueled raise signals a return to decentralized roots.
"This velocity isn't luck; it's validation of quantum-secured innovation," declared Krown CEO James Stephens. "While giants retrofit for tomorrow's threats, Krown launches ready - with $500K vanishing in hours, fully liquid, and community-owned. "With MainNet igniting on January 3, 2026, and 70% of $KROWN supply staked pre-launch, Krown isn't chasing history - it's rewriting the playbook.
Positioning for MainNet Launch
Krown's pre-sale success fuels momentum toward its MainNet launch on January 3, 2026, when the native $KROWN token will power the Camelot Ecosystem, including the recently launched Qastle hot wallet and upcoming KrownDEX - the world's first quantum-secured decentralized exchange. With 70% of the supply already staked pre-launch, Krown is poised for explosive post-MainNet growth, integrating quantum entropy from equity partner, Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0), to safeguard against both classical and quantum threats.
About Krown Technologies, Inc.
Krown Technologies, Inc. develops advanced blockchain, fintech, and quantum-secured products within the Camelot Ecosystem, delivering practical, enterprise-grade blockchain solutions that merge DeFi, AI, gaming, and post-quantum security.
About Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0)
Quantum eMotion Corp. is a Canadian deep-tech company commercializing Quantum Random Number Generator (QRNG) solutions for cybersecurity, blockchain, and fintech. Its QRNG2 hardware produces true quantum entropy to secure data and transactions against classical and post-quantum threats. Website: https://quantumemotion.com
Forward-Looking Information
This release may contain forward-looking statements relating to fundraising velocity, community growth, MainNet launch, and market positioning. Actual results may differ due to factors beyond Krown Technologies' control, including market conditions and technological developments.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273761
2025-11-09 20:295mo ago
2025-11-09 13:585mo ago
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.
If you're buying Eli Lilly (LLY 1.51%) stock today, odds are, it's because of its highly popular and successful GLP-1 drugs, Mounjaro and Zepbound. The former is approved to treat diabetes, while the latter is approved for weight loss. These drugs have generated billions in revenue for the company, and they are still in their early growth stages.
But while GLP-1 may be the flashiest and most exciting reason to invest in Eli Lilly, the business is far bigger than that. There are three other amazing growth opportunities for the business to tap into in the long run, which, if they pay off, could make the seemingly expensive stock look like a steal of a deal in the future.
Image source: Getty Images.
1. Kisunla
Last year, the Food and Drug Administration approved Kisunla, which is a treatment for people with early Alzheimer's disease. In clinical trials, the drug has shown that it can help slow cognitive decline in people with Alzheimer's.
The obvious problem is that by the time Alzheimer's is caught, it's often not in the early stages. But there could soon be ways to get ahead of the illness. Researchers from Mass General Brigham have recently developed a test that can be done at home that can be helpful in detecting cognitive impairment to identify people at risk of developing Alzheimer's, and it involves simply sniffing odor labels.
As the healthcare industry improves methods for detecting Alzheimer's in its early stages, that could unlock a massive opportunity for Kisunla to help more people earlier. While it's already a potential blockbuster drug (with peak sales estimated to be around $5 billion per year), early detection tests could unlock even more for the drug.
2. Radiopharmaceuticals
Eli Lilly is also investing in a novel approach to cancer treatment: radiopharmaceuticals. These types of drugs use radiation and specifically target unhealthy cells. This can make them more precise in their treatment, as a big problem with chemotherapy is that it can harm healthy cells. Radiopharmaceutical drugs have the potential to revolutionize cancer care and may lead to better outcomes for patients, especially those with hard-to-treat cancers.
Last year, Eli Lilly announced a collaboration with Aktis Oncology that involves a $60 million upfront payment as Eli Lilly works to develop radiopharmaceuticals using Aktis Oncology's miniprotein technology platform. In the year prior to that, Eli Lilly announced the purchase of Point Biopharma for $1.4 billion, which is another company that's involved in radiopharmaceuticals.
While it's still the early stages of radiopharmaceutical drug development for Eli Lilly, it's a promising opportunity that could pave the way for better treatment options and unlock more growth for the business in the long run.
3. AI-powered drug discovery
Most recently, Eli Lilly announced it would be partnering with chipmaker Nvidia to utilize artificial intelligence (AI) in drug discovery. With the help of AI, drug discovery can potentially become much more efficient and effective. By tapping into existing data and using AI to potentially uncover new opportunities more quickly, this could be the most exciting growth opportunity to watch out for.
However, it will take a while, and it could take until the end of the decade before there are any significant benefits from this initiative, according to Diogo Rau, chief information and digital officer for Eli Lilly. But it's a great example nonetheless of the company's pursuit of growth and innovation.
Today's Change
(
-1.51
%) $
-14.14
Current Price
$
923.30
Eli Lilly is a fantastic growth stock to buy and hold
Although the past 12 months haven't been terribly great for Eli Lilly, as the stock is up just 7%, this remains an excellent growth investment to hang on to for the long haul. The company's growth prospects look incredible, with not only GLP-1 treatments but the multiple opportunities I noted above.
This is why I'm confident that Eli Lilly will become the first healthcare stock to join the trillion-dollar club. This is an unstoppable business to invest in, and one that all growth investors should consider putting into their portfolios.
2025-11-09 20:295mo ago
2025-11-09 14:005mo ago
Disney, Coreweave, Occidental, Oklo, Flutter, and More Stocks to Watch This Week
We'll also see earnings reports from Oklo, Cisco, Tencent, On Holding, and more. This week's scheduled releases of the consumer and producer price indexes have been preempted by the government shutdown.
SummaryFirst Eagle U.S. Fund A Shares (without sales charge*) posted a return of 7.55% in third quarter 2025.Materials and industrials were the leading contributors among equity sectors, while consumer staples detracted and real estate was flattish.The gold price continued to set new record nominal highs during the quarter. Andrey David Piza Pulido/iStock via Getty Images
The following segment was excerpted from the First Eagle U.S. Fund Q3 2025 Commentary.
Portfolio Review U.S. Fund A Shares (without sales charge*) posted a return of 7.55% in third quarter 2025. Materials and industrials were the
Recommended For You
2025-11-09 20:295mo ago
2025-11-09 14:075mo ago
VFC DEADLINE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages V.F. Corporation Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action - VFC
November 09, 2025 2:07 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of V.F. Corporation (NYSE: VFC) between October 30, 2023 and May 20, 2025, both dates inclusive (the "Class Period"), of the important November 12, 2025 lead plaintiff deadline.
SO WHAT: If you purchased V.F. Corporation securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V.F. Corporation's turnaround plans. Specifically, defendants provided investors with material information concerning V.F. Corporation's turnaround plan ("Reinvent"), which in part focused on efforts to return the Vans brand to positive growth. The lawsuit alleges that defendants concealed that additional significant reset actions would be necessary to return the Vans brand to growth, and would result in significant setbacks to Vans' revenue growth trajectory. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the V.F. Corporation class action, go to https://rosenlegal.com/submit-form/?case_id=44811 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273728
2025-11-09 20:295mo ago
2025-11-09 14:115mo ago
Has Contrarian Michael Burry Found His Next Big Short? The Famed Investor Is Betting the Farm Against an Artificial Intelligence Stock That Is Up 1,290% Over the Past 5 Years
Burry was one of the investors who correctly predicted -- and profited enormously from -- the bursting of the housing market bubble.
Michael Burry of Scion Asset Management made a name for himself as one of the few investors who spotted the housing bubble of the mid-2000s before it popped, triggering first the mortgage crisis and then the Great Recession. He and his fund at the time reaped hundreds of millions of dollars in profits after purchasing credit default swaps on mortgage-backed securities that paid out when the value of those securities cratered. Burry, along with a handful of other investors who saw the mortgage crisis coming, was a subject of the bestselling book The Big Short, which was later made into a movie of the same name.
Burry has been bearish about the U.S. stock market broadly for several years now. But in his recent call, the former Stanford neurology resident seems more bearish than he has in the past -- or at least, he's being more outspoken about it. And in the third quarter, Burry made a big bet against a high-flying artificial intelligence stock that is up by more than 1,290% in the past five years.
Burry seems more committed to this short
In a recent 13F filing, Scion Asset Management disclosed that in the third quarter, the fund purchased 5 million put options with a notional value slightly over $912 million on AI data analytics company Palantir (PLTR +1.66%). Scion also purchased 1 million puts on Nvidia. The firm further sold many of its holdings from the second quarter and purchased several new long positions as well. Burry has frequently changed the composition of Scion's portfolio in recent years.
Image source: Getty Images.
He has been on and off of X, posting infrequently, sometimes when he is concerned about the state of the market. Interestingly, though, he seems a lot more outspoken lately. He's posted several tweets in recent weeks to assert that the market is in a bubble.
One of these tweets included several charts. One chart showed that cloud growth has slowed in recent years compared to the years prior; another showed that U.S. technology capital expenditure growth has reached a level not seen since the dot-com bubble; and the third showed how spending from Nvidia and OpenAI is fueling much of the AI sector.
These aren't the charts you are looking for.
You can go about your business. pic.twitter.com/ICldNUp2OI
-- Cassandra Unchained (@michaeljburry) November 3, 2025
I find it interesting that Scion submitted its 13F to the Securities and Exchange Commission before the required deadline. Banks, brokers, and institutional-scale investment managers like Burry must report on the contents of their portfolios as of the end of each quarter, no later than 45 days after the end of that quarter. For the third quarter, that would be Nov. 14. Many funds and managers wait until the very last day before they give the public that glimpse into their portfolios. For instance, Warren Buffett's Berkshire Hathaway never seems to file its 13Fs before the day of the deadline. Scion also filed its 13F on the same night Palantir reported earnings, another interesting coincidence.
An obvious short that has been hard to short
The idea that Palantir is overvalued is not a novel concept. The stock is up 156% this year and trades at close to 300 times forward earnings.
"If this was the greatest company that was ever created and we gave it the same multiples as, let's say, Nvidia in 2023, the stock still can get cut by two-thirds. And that would be like 35 times sales," Citron Research's Andrew Left, another famous short seller, said back in August.
Today's Change
(
1.66
%) $
2.90
Current Price
$
177.95
But shorting an AI stock like Palantir in what has been more or less a three-year bull market is a brave undertaking. The stock has garnered incredible investor enthusiasm, and the business operates in a hot sector that many believe will change life as we know it.
Palantir's third-quarter earnings results beat analysts' consensus estimates on both the top and bottom lines, and management also guided for higher revenue in the fourth quarter than Wall Street had expected. CEO Alex Karp expressed his displeasure with short sellers like Burry during an interview on CNBC.
"The two companies he's shorting are the ones making all the money, which is super weird," Karp said. "I do think this behavior is egregious, and I'm going to be dancing around when it's proven wrong."
Very few people doubt the capabilities of Palantir's software. The company's AI technology can gather data and use it to inform decision-making in ways that were never possible before. Numerous government departments and commercial businesses are now using the technology, and seemingly to great satisfaction. But every asset still has a price, and I personally don't feel comfortable investing in Palantir stock at this kind of valuation.
2025-11-09 20:295mo ago
2025-11-09 14:315mo ago
TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
WHAT IS THIS ABOUT: On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was “seeking various documents and information primarily relating to the Company’s disclosures regarding the development of the Company's prostate cancer therapeutic candidates.”
On this news, Telix’s American Depositary Share (“ADS”) price fell 10.44% on July 23, 2025.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
2025-11-09 20:295mo ago
2025-11-09 14:405mo ago
Northwest Healthcare Properties REIT Reaches a Deal with Vital for Internalization of Management Rights for NZ$214 Million
November 09, 2025 2:40 PM EST | Source: Northwest Healthcare Properties REIT
Toronto, Ontario--(Newsfile Corp. - November 9, 2025) - Northwest Healthcare Properties Real Estate Investment Trust (TSX: NWH.UN) (the "REIT" or "Northwest") today announces it has entered into a conditional agreement for the internalization of management (the "Internalization") at Vital Healthcare Property Trust ("Vital").
"We are pleased to enter into an agreement for the Internalization of Vital, which will deliver immediate operational and financial benefits for both Northwest and Vital," said Zachary Vaughan, Chief Executive Officer of Northwest. "Internalizing Vital's management is fully aligned with our strategy to simplify our business, reallocate capital back to North America, and create value for our unitholders. This transaction further strengthens our balance sheet and demonstrates our continued commitment to disciplined capital allocation. For Vital, the Internalization is expected to deliver enhanced returns to unitholders (including Northwest as Vital's largest unitholder) and solidifies Vital's position as a leading investor in and developer of healthcare infrastructure in the Australasian market."
As a result of this transaction, Northwest expects to receive NZ$214 million (approximately $170 million) in cash in exchange for its external management rights over Vital. Vital will fund the Internalization by way of a capital raise launched concurrently with the announcement today. Northwest will remain Vital's largest unitholder, with an approximate 24% equity interest post capital raise.
Northwest intends to use the proceeds from the Internalization to further reduce leverage and capitalize on accretive growth initiatives. Operational efficiencies from the Internalization are expected to include significant reductions in general and administrative expenses, simplified operations, and a lower headcount.
Closing of the Internalization is conditional on a number of matters, including Vital lender consents; regulatory approvals; and a Vital capital raise of at least NZ$175 million, net (approximately $140 million). The Internalization is expected to be completed on December 31, 2025, or, if more time is required to satisfy the closing conditions, in the first quarter of 2026.
Northwest will not participate in the upcoming Vital capital raise, which allows Vital to broaden its unitholder base and overall liquidity. Northwest has agreed to maintain it's existing unitholding until February 2026 and will maintain two representatives on Vital's Board based on its resulting equity holding.
Northwest will release its financial results for the third quarter ended September 30, 2025, on Tuesday, November 11, 2025, after the markets close. A conference call to discuss these results will be held on Wednesday, November 12, 2025, at 10:00 a.m. ET.
About Northwest
Northwest provides investors with access to a portfolio of high-quality international healthcare real estate infrastructure comprised as at August 12, 2025, of interests in a diversified portfolio of 168 income-producing properties and 15.8 million square feet of gross leasable area located throughout major markets in North America, Australasia, Brazil and Europe. The REIT's portfolio of medical outpatient buildings, clinics, and hospitals is characterized by long-term indexed leases and stable occupancies. Northwest leverages its global workforce in eight countries to serve as a long-term real estate partner to leading healthcare operators. For additional information please visit: www.nwhreit.com.
Forward-Looking Statements
This press release may contain forward-looking statements with respect to the REIT, its operations, strategy, financial performance and condition. These statements generally can be identified by words such as 'may', 'will', 'expect', 'estimate', 'anticipate', 'intends', 'believe', 'normalized', 'contracted', or 'continue' or the negative thereof or similar variations. Forward-looking statements in this press release may include statements concerning the expected completion of the Internalization, the use of proceeds from the Internalization, the efficiencies and other benefits expected to be received from the Internalization, the REIT's relationship with Vital going forward and long-term value for unitholders. The REIT's actual results and performance discussed herein could differ materially from those expressed or implied by such statements. The forward-looking statements contained in this press release are based on numerous assumptions which may prove incorrect, and which could cause actual results or events to differ materially from the forward-looking statements. Such assumptions include, but are not limited to (i) the successful completion of the Internalization, including satisfaction of all necessary closing conditions, (ii) the REIT being able to realize the expected operational benefits and cost savings from the Internalization, (iii) the REIT's properties continuing to perform as they have recently, (iv) various general economic and market factors, including exchange rates remaining constant, local real estate conditions remaining strong, and interest rates remaining at current levels or decreasing, and (v) the availability of equity and debt financing to the REIT and the REIT's ability to refinance, or extend the maturity of, its existing debt. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations, including that the transactions contemplated herein are completed. Important factors that could cause actual results to differ materially from expectations include, among other things, the inability to successfully complete the Internalization, the inability to realize the benefits of the Internalization, general economic and market factors, competition, changes in government regulations, and the factors described under 'Risks and Uncertainties' in the REIT's Annual Information Form and the risks and uncertainties set out in the REIT's most recent MD&A which are available on SEDAR+ at www.sedarplus.ca.
These cautionary statements qualify all forward-looking statements attributable to the REIT and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release, and, except as expressly required by applicable law, the REIT assumes no obligation to update such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273759
2025-11-09 20:295mo ago
2025-11-09 15:005mo ago
NVIDIA Shares Dropped 7% This Week: 3 Catalysts For the Fall
Shares of NVIDIA (Nasdaq: NVDA) dropped 7.1% this week, sinking sharply after hitting a high of $211.34 on Monday morning.
2025-11-09 20:295mo ago
2025-11-09 15:025mo ago
FLYE DEADLINE NOTICE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Fly-E Group, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - FLYE
November 09, 2025 3:02 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fly-E Group, Inc. (NASDAQ: FLYE) between July 15, 2025 and August 14, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Fly-E securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Fly-E class action, go to https://rosenlegal.com/submit-form/?case_id=44575 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the safety of Fly-E's lithium battery which in turn took a material toll on its E-vehicle sales revenue, despite making lofty long-term projections, Fly-E's forecasting processes fell short as sales continued to decline and operating expenses increased, ultimately, derailing Fly-E's revenue projections. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Fly-E class action, go to https://rosenlegal.com/submit-form/?case_id=44575 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273729
2025-11-09 19:295mo ago
2025-11-09 12:165mo ago
Michael Saylor Hints Bitcoin Buy As Goldman Sachs Predicts Three Fed Rate Cuts
CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.
Michael Saylor’s Strategy may be preparing another Bitcoin purchase as Goldman Sachs forecasts a wave of interest rate cuts by mid-2026. The Strategy founder’s latest post, captioned “Best continue,” comes as the investment bank expects monetary easing to begin as early as December.
Saylor’s Post Sparks Speculation Of Fresh Bitcoin Accumulation
Saylor’s Strategy now holds 641,205 BTC, valued at around $65.45 billion. With an average cost of $74,064 per coin, the firm is sitting on roughly $18 billion in unrealized gains. The chart shared by Saylor shows 85 separate Bitcoin purchases. Last week, Strategy increased its BTC holdings with a $21 million purchase.
His post immediately reignited speculation that another accumulation phase may be underway. This follows Saylor’s direct call to buy more Bitcoin as the leading cryptocurrency traded around $101,000.
₿est Continue pic.twitter.com/gDnOoBH7Ad
— Michael Saylor (@saylor) November 9, 2025
Each previous orange marker on Saylor’s graph represented a Bitcoin purchase, even during heavy downturns in 2022. The consistent buying lowered the firm’s cost basis, giving Strategy one of the strongest long-term positions among corporate Bitcoin holders.
Goldman Sachs Sees Three More Fed Rate Cuts
At the same time, Goldman Sachs predicts a major policy shift that could support Bitcoin’s next leg higher. The bank’s chief U.S. economist, David Mericle, said the Federal Reserve is likely to cut rates three times between December 2025 and June 2026, bringing the federal funds rate down to 3–3.25%.
Goldman’s forecast contrasts Fed Chair Jerome Powell’s cautious optimism regarding any rate cuts this year. According to him, inflation is dropping and the labor market is weakening. Even with the cautious wording from Powell, the bank analysts still believe there are still reasons for additional rate cuts.
Reduction in interest rates normally increases liquidity and risk appetite in the market, which most traders consider as being bullish to cryptocurrencies. Lower interest rates and decreasing bond yields usually encourage more investors to purchase assets such as Bitcoin.
Bitcoin is currently being traded at $103,352 with an increase of 1.04% in the last 24 hours as presented by the TradingView.
2025-11-09 19:295mo ago
2025-11-09 12:305mo ago
Dogecoin Rebounds 2.29% After a Month-Long Decline: Is a Macro Cycle Reversal Starting?
Dogecoin gains 2.29% in 24 hours after a steady month-long decline of over 25% in value.
Market cap rises to $27.01B while trading volume drops 53%, showing reduced short-term activity.
Price fluctuates between $0.170 and $0.178, ending the day with controlled market participation.
Historical data shows recurring cycles with growth peaks of 5,858%, 21,457%, and projected 4,447%.
Current cycle trends near $0.197, with analysts monitoring potential movement toward the $7.21 level.
The Dogecoin price has been trending negatively for a month, with a 25.28% decline in its value. Despite the dip in its price, market analysts have hinted at a trend reversal as the meme coin eyes a potential macro cycle that will lead to a new bullish trend.
Dogecoin Current Market Action Revealed
According to the latest CoinMarketCap data, as of the time of press, Dogecoin was trading at $0.1780, representing a 2.29% gain over the past 24 hours. The market capitalization increased to $27.01 billion, up 2.3% from the previous day. The 24-hour trading volume fell sharply by 53.39% to $1.46 billion, indicating reduced short-term trading activity despite the price rise.
Source: CoinMarketCap
During the 24 hours, the price fluctuated between approximately $0.170 and $0.178, showing moderate volatility. The price initially declined during early trading hours, reaching its lowest point near $0.171 before beginning a gradual recovery.
A strong upward momentum emerged later in the day, pushing Dogecoin above $0.176, followed by a final sharp rise to $0.178. The volume-to-market cap ratio stood at 5.4%, suggesting controlled market participation relative to capitalization. Overall, the trading chart depicted a recovery trend after earlier weakness, marking Dogecoin’s steady rebound throughout the observed session.
DOGE Market Cycles Trace Repetitive Growth Patterns Through the Years
Dogecoin’s long-term chart tracks three distinct market cycles between 2014 and 2027, showing clear phases of growth and correction. An observation by Bitcoin Census reveals that the first cycle began near zero and reached $0.0113, marking a 5,858 percent rise before declining sharply.
Source: X
During the second cycle, starting around 2018, prices moved steadily upward before a sudden climb to $0.7464, gaining 21,457 percent. After the rally, values fell and moved downward through 2022, forming a clear correction phase that lasted several months. The third cycle displays a gradual rise beginning in 2023, where prices remain near $0.197 within an upward channel.
Currently, an uptick is expected as the data also projects a potential peak near $7.21, equating to a 4,447 percent gain. Each observed phase follows a similar rhythm of accumulation, acceleration, and retracement, reflecting a consistent geometric pattern across time. Dogecoin’s chart, therefore, records measurable repetition in its historical and projected price structure.
2025-11-09 19:295mo ago
2025-11-09 12:525mo ago
XRP Developer Predicts $5,000 Price Surge—Community Reacts to Bold Claim
The XRP community is buzzing once again after Vincent Van Code, a prominent developer and longtime supporter of the token, issued an extraordinarily bullish forecast—claiming that XRP could one day soar to $5,000 per coin “that quickly.”
2025-11-09 19:295mo ago
2025-11-09 13:005mo ago
Bitcoin UTXO Age Bands Put Local Bottom At $95K — Here's Why
After a disappointing performance during the week, the price of Bitcoin has continued its sluggish action over the weekend. According to data from CoinGecko, the premier cryptocurrency has been hovering around the $102,000 level over the past 24 hours.
While this current choppy price action seems like an improvement from the severe downturn witnessed in recent days, it doesn’t particularly bring calm to the world’s largest cryptocurrency. Interestingly, the latest on-chain data suggests that the Bitcoin price might still be at risk of further correction in the coming days.
Why BTC Price Might Find Bottom Around $95,000
In a November 8 post on the social media platform X, on-chain analyst Burak Kesmeci predicted the local bottom for the price of Bitcoin. According to the crypto pundit, the flagship cryptocurrency could fall to as low as $95,000 before seeing relief and perhaps rebounding to new price highs.
The relevant metric here is the Realized Price of Unspent Transaction Output (UTXO) age bands, which evaluate the holding pattern of different investor classes through their different realized prices. The UTXO age bands metric tracks the average price at which Bitcoin holders purchased their coins compared to how long they’ve held the assets.
The age bands under focus in Kesmeci’s analysis are the 1-week to 1-month group (green line) and the 1-month to 3-month cohort (purple line), which offer insight into short-term holders’ behavior and overall market sentiment. According to the on-chain analyst, the green line has crossed below the purple line three times in 2025.
Source: @burak_kesmeci on X
Kesmeci noted that this cross often preceded short-term corrections, including the ones seen on February 24 ($99,000 to $76,000) and September 8 ($117,000 to $109,000). Similarly, this cross occurred on November 1, with the Bitcoin price falling from $110,000 to $99,000.
Furthermore, the average dip suffered by the Bitcoin price on these three occasions stands at around 13.3%, with a 45-day consolidation period. Based on this historical pattern, Kesmeci expects the Bitcoin price bottom to form around the $95,000 and $96,000 region after the most recent crossing of the 1-week to 1-month band below the 1-month to 3-month band.
Kesmeci concluded:
In short, long-term investors are in the red, and this is an undesirable situation for a bull cycle. However, if history repeats itself, Bitcoin may “catch its breath” once more in this region and prepare the ground for a new rise.
Bitcoin Price At A Glance
As of this writing, the price of BTC stands around $102,440, reflecting a nearly 1% decline in the past day.
The price of BTC on the daily timeframe | Source: BTCUSDT chart on TradingView
Featured image from iStock, chart from TradingView
Key Takeaways
Why did FET fall this week?
Overbought signals and $13 million Open Interest drop triggered outflows and profit-taking.
What suggests a rebound ahead?
Spot inflows of $6.5 million, RSI near 48, and MACD’s bullish crossover hint recovery potential.
Artificial Superintelligence Alliance [FET] saw a wave of outflows, leading to a steep 14% decline in six days. Market sentiment stayed bearish, with monthly outflows down 40%.
The recent drawdown, while dragging investments notably lower, could be a simple corrective move. Here’s what AMBCrypto’s analysis found.
Overbought territory pushes FET lower
Market analysis revealed that FET’s recent price drop was triggered as the asset entered overbought territory and liquidity outflow surged.
The Bollinger Bands chart showed that FET traded within the overbought zone, marked with a circle on the chart below. This zone is reached when the price crosses above the green line — historically a strong liquidity wall — where large sell orders typically cluster.
Source: TradingView
Outflows from the Derivatives market also intensified the decline, as open interest dropped sharply in the last 24 hours.
Data from CoinGlass showed that over $13.2 million in contract positions were closed, with $1.4 million coming from liquidations.
Ideally, the price was moving toward the middle Bollinger Band at $0.2588, which could provide support and aid a potential rebound.
However, if this level fails to hold, FET could slide further toward the lower band at $0.1837, which has historically acted as a key support level.
Interestingly, the data indicates that the decline could merely be corrective, with a potential rally likely to follow.
A short corrective phase
This phase may simply be a short-term correction, as market sentiment shows quick liquidity returning to the market.
CoinGlass’s Spot Exchange NetFlow data showed that amid the price decline, Spot investors spent over $6.5 million scooping up FET within two days — suggesting buying activity could extend into the new week.
Source: CoinGlass
While Open Interest dropped $13 million, the Funding Rate climbed to 0.0083%, showing long traders continued paying shorts.
That positioning often signals confidence in a rebound.
Momentum is slow, but bulls show signs of revival
Technical indicators such as the Relative Strength Index (RSI) and Moving Average Convergence Divergence (MACD) showed that selling pressure persists but is fading.
The RSI has slipped slightly below 50, signaling weakened buying momentum. However, the MACD is trending upward, indicating that bullish sentiment remains active — a potential sign of recovery.
Source: TradingView
If the RSI makes an upward reversal and the MACD continues to trend into the positive zone, FET could be primed for a rebound.
2025-11-09 19:295mo ago
2025-11-09 13:015mo ago
Bitcoin treasury bear market ‘gradually' ending as renowned short seller closes MSTR/BTC position
Renowned short seller James Chanos has officially closed his $MSTR/Bitcoin hedged trade after 11 months, marking an end to his high-profile bet against Bitcoin-linked equities and Strategy stock. The unwinding of institutional short positions is a trend reversal indicator that could mean the worst for Bitcoin treasury companies is behind them.
The bitcoin treasury ecosystem has been battered and bruised in recent weeks. Most companies’ stock is significantly down from peaks earlier this year, and analysts have been calling investors to short stocks like MSTR. They fervently cautioned that a bubble was present in bitcoin treasury companies, and it was about to unceremoniously burst.
But just as the shorting pressure was reaching fever pitch, a reprieve may be on the horizon. On Saturday, Pierre Rochard, CEO of The Bitcoin Bond Company and treasury sage, declared that the bear market for Bitcoin treasury companies is “gradually coming to an end.”
To his mind, the unwinding of institutional shorts, one of the cleanest signals in the game, suggests the tide may be turning:
“Expect continued volatility, but this is the kind of signal you want to see for a reversal.”
Not exactly champagne-popping territory, but for those who have waded through endless bearish sentiment and mNAV headaches, hope is about as welcome as rain in a desert.
James Chanos unwinds his Bitcoin treasury shortOne of those shorts belonged to none other than James Chanos, the renowned investor and long-time foe of anything with “Bitcoin” on the label.
Chanos has officially closed out his $MSTR/Bitcoin hedged trade after 11 months, marking the end of a high-profile bet against the poster child for corporate BTC accumulation. For those keeping score at home, MicroStrategy is now holding over 640,000 BTC, and steadily buying every dip as if Michael Saylor never heard of risk management.
Chanos confirmed the move on X, sparking a flurry of takes and “is this the bottom?” threads across crypto Twitter. He posted:
“As we have gotten some inquiries, I can confirm that we have unwound our $MSTR/Bitcoin hedged trade as of yesterday’s open.”
The institutional players changing the gameMeanwhile, the institutional mood is quietly shifting. Traditional finance heavyweights are entering the chat; not as naysayers, but as stakeholders, participants, and, crucially, treasury innovators.
JPMorgan’s recent maneuvering in BlackRock’s spot Bitcoin ETF, plus a slew of custody and settlement deals popping up in the news, point to a world where corporate Bitcoin adoption is less “wild west,” more boardroom strategy. Whether it’s pushing up ETF flows, tweaking treasury yield strategies, or rating digital assets on par with real-world securities, the shift is happening beneath the surface.
Of course, none of this suggests an imminent escape from volatility for Bitcoin treasury companies. Bitcoin remains haunted by the ghosts of macro uncertainty and regulatory U-turns. But the closure of headline shorts, especially those run by high-profile skeptics like Chanos, isn’t just about dollars; it’s a psychological turning point.
For both Bitcoin’s price and the institutional narrative, the message is clear: the worst may just be behind us, and the next chapter isn’t being written by the usual suspects.